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ABSTRACT
Serotonin (5-Hydroxytryptamine, 5-HT) mediates vasoconstriction and vasodilation in 
the normal coronary circulation of various animal species. In the presence of coronary 
artery disease serotonin may inhibit coronary collateral formation and stimulate 
predominantly vasoconstriction. This study tested the effect of ketanserin, a selective 
5-HT2 receptor antagonist and platelet aggregation inhibitor, on ischaemic myocardium 
blood flow and coronary collateral formation following coronary artery occlusion in 
primates.
Fifteen baboons were subjected to left-anterior descending coronary artery ligation and 
thrombus formation. Haemodynamics and regional myocardial blood flows 
(microsphere technique) were measured before, 45 min after and one week after 
coronary artery occlusion.
There was no significant difference in the haemodynamic measurements, gross infarct 
size or infarct-ischaemic zone myocardial blood flow in the experimental group 
(ketanserin 1 mg/kg daily, n = 9) compared with the control group (injectable water, 
n = 6). In both groups there was a similar significant increase in the blood flow ratio 
of infarct-ischaemic: normal myocardium blood flow at one week compared with shortly 
after coronary occlusion. Thus selective 5-HT2 receptor blockade has neither an adverse 
nor a protective effect on the myocardial infarct following acute thrombotic coronary
occlusion in baboons.
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PREFACE
My interest in the field of myocardial ischaemia developed after the completion of my 
undergraduate medical training, during my term as a medical intern. I noticed then that 
a large number of patients with myocardial ischaemia were suffering from repeated 
myocardial infarction, despite invasive therapeutic interventions such as coronary artery 
bypass surgery or coronary artery balloon angioplasty. The possibility of an effective 
non-invasive cardioprotective pharmacological intervention, for the prevention and 
management of ischaemic heart disease, has led to my investigation of the effects of 
serotonin on the coronary collateral circulation under conditions of primate 
experimental myocardial ischaemia.
CHAPTER 1: INTRODUCTION
Serotonin (5-hydroxytryptamine, 5-HT), a vasoactive monoamine found and stored in 
platelets, has an adverse effect on the regional blood flow following peripheral arterial 
ligation or thrombosis (Nevelsteen et al. 1984; Blackshear et al. 1985; Orlandi, 1986). 
Arterial thrombotic occlusion reduces the subsequent formation of a peripheral 
collateral circulation in cats (Imhoff, 1961; Blackshear et al. 1985); peripheral arterial 
collateral formation and/or function is inhibited by serotonin in the cat, dog, rat and 
rabbit (Hollenberg, 1987); and the 5-HT2 receptor antagonist, ketanserin, inhibits 
serotonin-induced femoral artery constriction in dogs (Blackshear et al. 1985) and 
improves post-thrombotic peripheral collateral function in cats (Nevelsteen et al. 1984).
The normal in vivo response to serotonin is one of large artery vasoconstriction and 
microvascular vasodilation with a net increase in blood flow (Housten and Vanhoutte, 
1986). However, in pathology such as atherosclerosis, the response to serotonin is 
predominantly vasoconstriction with a net reduction in blood flow (Heistad, 1984; 
Blackshear et al. 1985; Orlandi, 1986). This effect may be due to increased vascular 
myocyte exposure to serotonin following endothelial damage (Cocks and Angus, 1983; 
Lamping et al. 1985; Vanhoutte, 1986) or increased local serotonin concentrations 
following platelet aggregation in thrombi at the sites of arterial occlusion (Housten and 
Vanhoutte, 1986). Activation of endothelial 5-HTr like receptors leads to coronary 
artery vasodilation while stimulation of myocyte 5-HT2 and a minority of 5-HTr like 
receptors produces vasoconstriction (Blackshear et al. 1985; Bradley et al. 1986;
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Golino et al. 1991). 5-HT2 receptors are also found on platelets, where, in addition to 
propagating platelet aggregation, they facilitate platelet release of serotonin and other 
vasoactive substances (Housten and Vanhoutte, 1986; Vanhoutte, 1986).
Coronary arterial collaterals are known to develop in response to acute and chronic 
myocardial ischemia (Fujita et al. 1988). Serotonin is a vasoactive agent in coronary 
arteries, mediating vasoconstriction, vasodilation and cyclic flow variations (Ashton et 
al. 1986; Bush, 1987; Chu and Cobb, 1987;). The aim of this study was to determine 
whether selective 5-HT2 receptor blockade improves regional myocardial blood flow 
following coronary artery occlusion and thrombosis.
1CHAPTER 2; LITERATURE REVIEW
2.1 MYOCARDIAL ISCHAEMIA AND MYOCARDIAE 
INFARCTION.
2.1.1 DEFINITIONS.
Myocardial ischaemia refers to cellular oxygen deprivation (hypoxia), nutrient 
deprivation and the accumulation of waste products resulting from decreased myocardial 
perfusion of blood. The term ischaemic heart disease defines a disease spectrum of 
broad etiology, with the common factor being an imbalance of oxygen demand and 
oxygen supply, leading to ischaemic cell changes, and is usually the result of 
atherosclerosis. Myocardial infarction is a localised area of complete ischaemic cell 
necrosis (cell death), and more commonly arises from vascular thrombosis 
superimposed on atheromatous coronary plaques. Myocardial infarction is 
predominantly a disease of the left ventricle and interventricular septum, but the area 
which is damaged may extend into the right ventricle or even the atria if large. Some 
of the clinical consequences of ischaemic heart disease include decreased myocardial 
contractility with a decrease in systolic cardiac performance, diastolic dysfunction 
(ventricular filling abnormalities) and irregularities of heart rhythm.
22.1.2 MYOCARDIAL INFARCTION IN THE BABOON MODEL.
2.1.2.1 THE BABOON’S NORMAL REGIONAL MYOCARDIAL BLOOD
FLOW.
In the experiment of Lubbe et al. (1974) it was found that there was an equal 
distribution of regional blood flow to the left ventricular epicardium and endocardium 
prior to coronary occlusion, but in the experiment of Lavallee et al. (1984) regional 
myocardial blood flow was found to be distributed primarily to the endocardium in 
conscious baboons (prior to myocardial infarction). The latter finding has also been 
noted in conscious chair-trained baboons by Vatner et al. (1987). King et al. (1985) 
showed that the degree of spatial heterogeneity of local myocardial flows in awake 
baboons is similar to that of the anaesthetized animals; that the degree of myocardial 
blood flow heterogeneity is marked, and that this pattern of regional flow heterogeneity 
tended to remain stable with time: They did not comment on endocardial versus 
epicardial blood flows.
2.1.2.2 DISTRIBUTION OF THE BABOON MYOCARDIAL INFARCTION.
The transmural distribution of a myocardial infarction has been compared in different 
animal species. Flameng et al. (1986) noted that, following left anterior descending 
coronary artery ligation, dogs developed a predominantly subendocardial infarct 
whereas that of baboons was primarily subepicardial (human infarcts are usually
3transmural or subendocardial). In opposition to this Geary et al. (1983) found that 
baboons evolved sub-endocardial and mid-myocardial infarcts, rather than subepicardial 
infarcts. Flameng et al. (1986) has also demonstrated that the baboon infarct size, when 
expressed as a percentage of the perfusion bed of the occluded coronary artery, is 
greater than that found in dogs. This fact may be related to the higher myocardial 
metabolic demand of a baboon heart (as judged by the higher heart rates and blood 
pressures found in baboons, when compared with dogs).
Barker et al. (1980) reported that, in both baboons and monkeys, infarcts following 
coronary occlusion were transmural (i.e. all of epi-, mid- and endocardial). Lubbe et 
al. (1974), Lavallee et al. (1984), Heyndrickx et al. (1985) and Ruf et al. (1986) have 
noted that reductions of blood flow in the epi-, mid- and endo- cardial thirds of 
myocardial infarcts following coronary occlusion in baboons were similar, pointing 
towards the development of mainly transmural infarcts in the baboon model. In 
addition, Crozatier et al. (1978), Geary et al. (1981)and Vatner et al. (1987) have 
histologically confirmed the presence of transmural infarction in baboons, although the 
above-mentioned Vatner study also showed a prominent rim of both endocardial and 
epicardial infarct sparing. In any of the above cases mentioned, the site of infarct 
produced following coronary occlusion in the baboon appears to mimic more closely 
the site found in humans, than other animal species do.
42.1.3 THE PATHOGENESIS OF MYOCARDIAL INFARCTION.
(Maroko et al. 1971; Van der Werf, 1980; Francis and Cohn, 1984; Katz, 1983; 
Henderson and Marcus, 1984).
An imbalance between myocardial oxygen supply and demand results in myocardial 
ischaemia and/or infarction: Pharmacological interventions which reduce the myocardial 
oxygen demand or increase the oxygen supply may therefore affect infarct size and 
improve heart function following an infarct (Maroko and Braunwald, 1975).
2.1.3.1 MYOCARDIAL OXYGEN SUPPLY.
Myocardial oxygen supply is dependent on coronary arterial blood flow which in turn 
is influenced by perfusion pressure, aortic blood flow, coronary systolic and diastolic 
vascular resistances (neurogenic and autoregulatory controls) and the presence of a 
functioning coronary collateral circulation, as follows:
1) Coronary perfusion pressure (the difference between proximal coronary artery 
pressure and coronary sinus pressure): Since pressure in the large coronary arteries 
branching from the ascending aorta is identical to aortic pressure and, since at the 
venous side coronary sinus pressure equals right atrial pressure, the coronary perfusion 
pressure may be taken as the difference between aortic pressure (diastolic) and right 
atrial pressure.
52) Myocardial extravascular resistance (systolic compression of coronary vessels): The 
tension generated during ventricular systole in the myocardium is enough to collapse 
subendocardial vessels and to severely restrict flow to the subepicardial myocardium. 
The degree of this flow-limiting tension is dependent on the pressure developed by the 
left ventricle, the radius of the ventricle and the ventricular wall thickness (the Laplace 
equation), as well as on myocardial contractility and heart rate (since heart rate 
influences the relative lengths of systole and diastole and therefore the duration of 
myocardial vascular occlusion).
3) Diastolic coronary resistance: Is mainly determined by the arteriolar diameter, which 
is controlled in the major part by local metabolic factors (the local partial oxygen 
pressure being the most important regulatory factor of these). Metabolic autoregulation 
is dominant over neural and humoral regulation. The known metabolic mediators of 
coronary artery vasodilation include adenosine, potassium ions, hydrogen ions, various 
prostaglandins, histamine and bradykinin.
4) Autoregulation: Although an autoregulatory capacity (the inherent ability of blood 
vessels to compensate for excessive changes in intra-luminal blood pressure) exists in 
the coronary circulation, it is usually coupled with metabolic regulation, and tends to 
be more effective in the subendocardial than in the subepicardial layers of the left 
ventricle.
5) Neural control: The direct effects of sympathetic stimulation produce modest
6coronary constriction while the indirect effects (an increase in left ventricular 
myocardial oxygen consumption) lead to a drop in coronary vascular resistance. Vagal 
stimulation may occasionally produce indirect coronary arteriolar constriction because 
of the associated decline in myocardial oxygen consumption (stimulation of myocardial 
M2 receptors). However, the usual nett effect of both sympathetic or parasympathetic 
stimulation is an increase in coronary blood flow.
6) Humoral control: The major circulating humoral agents which influence coronary 
tone are catecholamines, angiotensin-II and thyroid hormone. More recently, the 
humoral substances acetylcholine, serotonin and thrombin have been found to be 
important modulators of coronary vascular tone.
2.1.3.2 MYOCARDIAL OXYGEN DEMAND.
Cardiac muscle utilises predominantly fatty acids and lactate as substrates for oxidation. 
The energy derived from the breakdown of these products is stored in the form of 
adenosine triphosphate (ATP). The heart metabolises as a predominantly aerobic organ, 
but even under conditions of adequate oxygen availability lactate is consumed by 
cardiac muscle. As a result the coronary sinus lactate concentration is usually less than 
that of arterial blood.
Myocardial oxygen demand is governed primarily by the intracardiac systolic pressure 
(myocardial wall stress or tension), the degree and rate of myocardial fibre shortening
7(inotropic state or contractility) and heart rate (the duration of the systolic period). 
Basal myocardial metabolic rate, external cardiac work (force times distance) and 
energy of activation also influence myocardial oxygen demand to a lesser degree. 
Clinically the product of aortic systolic pressure (which is nearly the same as left 
ventricular systolic pressure) and heart rate, the so-called rate-pressure product, is often 
used as an indicator of myocardial oxygen demand. However, other factors such as an 
increased myocardial contractility may place a higher value on oxygen demand than that 
calculated using the rate-pressure product. It has been noted recently that infarct size 
in baboons is determined by the size of the perfusion bed of the occluded coronary 
artery and the duration of that occlusion rather, than by the rate-pressure product or by 
collateral blood flow (Flameng et al. 1990). Since myocardial oxygen demand 
influences the production of numerous vasoactive metabolites, this demand must play 
an important role in the regulation of coronary blood flow.
2.1.3.3 THE CONCEPT OF INFARCT SIZE LIMITATION.
Interventions which decrease myocardial oxygen demand or increase myocardial oxygen 
supply have been shown to reduce the extent of acute ischaemic injury ( Rogers et al. 
1982; Heyndrickx etal. 1985). Any intervention therefore which, through manipulation 
of the above-mentioned factors that control coronary blood flow increases the coronary 
blood flow, may limit the size of an infarct. A major portion of the jeopardised 
myocardium within the territory of an occluded coronary artery is preserved by low 
blood flow perfusion. This low-flow perfusion gains access to the affected arterial
8system by vascular collaterals: Yet, with prolonged occlusion, even this low-flow area 
succumbs to infarction. The area encapsulating the severely ischaemic core of an area 
of regional ischaemia, and separating it from the surrounding normal tissue, consists 
of a zone of intermediate flow and intermediate cell injury, and is known as the "border 
zone": The existence of the border zone implies that a wavefront of slowly progressing 
infarction is associated with prolonged ischaemia and/or with a recession of the 
collateral blood flow. Thus potentially, infarct size may be limitable by the 
pharmacological manipulation of the development of vascular collaterals and/or by a 
change in the resistance to blood flow of those collaterals supplying an ischaemic 
region.
2.2 THE CORONARY COLLATERAL CIRCULATION.
2.2.1 INTRODUCTION
A coronary collateral channel is an initially unused vascular pathway that becomes 
functional after failure of the existing coronary circulation to permit normal blood 
flows, such as occurs in the presence of ischaemic heart disease. The collateral 
network, which varies in different species, may consist of either a single or an 
interconnecting system of channels and is either pre-existing or newly-developed. The 
anatomical presence of collaterals has been researched and confirmed in the canine, 
porcine, human and non-human primate myocardium, however the functional 
significance of these channels is still controversial.
92.2.2 STIMULATION OF NEWLY DEVELOPED COLLATERALS.
Theories of the mechanisms contributing towards collateral vessel growth include both 
biochemical factors (hormones from mesoderm-derived heart cells and platelets) and 
physical factors which induce a mitogenic response in the ischaemic myocardial 
microcirculation’s endothelial cells (Schaper et al. 1988): The ischaemic myocardium 
produces biochemical signals, the different types of which are as yet uncertain, but 
fibroblast growth factors (Montesano et al. 1990), platelet derived growth factors and 
tumor derived growth factors may all be involved. These biochemical signals trigger 
cellular transformation and mitosis in pre-existing and newly-developing collateral 
vessels. The extracellular matrix (collagen) is also implicated as a solid-phase inducer 
of capillary morphogenesis.
Schaper et al. (1978), using an experimental model of coronary occlusion in the dog, 
concluded that the determinants of coronary collateral blood flow include the coronary 
perfusion pressure, the degree of extravascular compression of underperfused 
myocardium by myocardial contraction, the size of the area-at-risk and the genetic 
factors mentioned above. Thus, physical forces, which include the gradient of pressure 
along inter-connecting arteriolar channels, changes in tangential wall stress (eg. as a 
consequence of vessel diameter changes and therefore changes in vessel wall tension) 
and increments in viscous drag and shear stress following increased blood flow 
velocity, are also implicated in the moulding of collateral growth and in the generation 
of mitogenic biochemical signals.
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2.2.3 ANIMAL MODELS AND COLLATERAL ANATOMY.
The capacity to develop a coronary collateral circulation varies among and within 
species: Dogs show a well developed collateral circulation distributed primarily in the 
epicardium, compared with the less prominent collateral circulation which is found in 
pigs and baboons and which is situated primarily in the subendocardium and 
transmurally (Crozatier et al. 1978; Verani, 1983; Flameng et al. 1990).
Although the dog has frequently been used as an experimental model for coronary 
occlusion/myocardial infarction and the collateral circulation, the main advantage of the 
baboon model is it’s phylogenetic similarity to man. The coronary artery anatomy of 
baboons mimics more closely than other species do that of the coronary artery 
distribution of man (Flameng et al. 1986). Weisse et al. (1976) found that the heart 
weight to body weight ratio in baboons (mean 5.2 grams per kilogram) is similar to that 
found in man (mean 5.3 grams per kilogram) and less than that of dogs, but that the 
collateral response to coronary occlusion was similar in both dogs and baboons in terms 
of their resultant haemodynamic and metabolic changes. Flameng et al. (1986) showed 
that, following left anterior descending coronary artery occlusion in baboons and dogs, 
subendocardial collateral flow was higher than subepicardial collateral flow in baboons 
(and therefore similar to that of humans) while in dogs the subendocardial collateral 
flow was less than the subepicardial collateral flow. Opie et al. (1983) have however 
pointed out that, although the baboon is phylogenetically close to man in terms of its 
cardiac receptors, immunology and coronary artery anatomy, the degree of the
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collateral circulation remaining after coronary occlusion is often less than that 
demonstrated following ischaemic heart disease in humans.
Existing epicardial collaterals in the canine model consist of endothelium and several 
smooth muscle layers (similar to arterioles of 20 to 60 /xm diameter), whilst those of 
the pig are closer to capillaries or pre-capillary arterioles (Schaper et al. 1988). 
Transformed or newly-developed collaterals of all class and size (up to 1mm diameter) 
of arterial and capillary blood vessels have been noted following coronary artery 
occlusion in the human, porcine and canine models. The anatomy of newly-developing 
collaterals has been closely investigated in the canine model by Schaper et al. (1988); 
the collaterals, which were found to develop in a narrow sub-epicardial zone adjacent 
to the ischaemic region, first appear thin-walled and vein-like, but then develop sub- 
intimal muscular proliferation and later show both medial and adventitial blood vessel 
wall layers.
2.2.4 THE FUNCTIONAL SIGNIFICANCE OF CORONARY COLLATERALS.
An important factor of ultimate infarct size is the remaining blood flow to ischaemic 
tissue following a restriction of blood flow. It is reasonable therefore to expect a 
reduction in infarct size in the presence of good collateral blood flow, following 
coronary occlusion. The degree of collateral blood flow existing 5 minutes after 
ligation of a major coronary artery (expressed as a percentage of non-ischaemic blood 
flow) has been assessed in various species using radioactive microspheres, and shown
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to be; dog 16%, cat 12%, rat 6%, baboon 2% (n = 6), rabbit 2% and pig 0.6% 
(Maxwell et al. 1987). Lubbe et al. (1974) has however noted in the baboon that, as 
early as 10 minutes after left anterior descending coronary artery ligation, there was 
a considerable blood supply (5% to 15%) to the border zone of the resulting infarct, 
and that this blood flow stemmed from the unligated adjacent coronary artery. He 
concluded that in the baboon the blood flow to the infarct edge is dependent on the 
existence of readily available collateral circulation channels.
Crozatier et al. (1978) noted that baboons had a far smaller index of collateral flow 
(using both retrograde flow and histology techniques) than dogs, but that both animals 
exhibited a gradual increase in the collateral blood flow over one month, following 
coronary occlusion. Rivas et al. (1976), Bishop et al. (1976) and Judgutt et al. (1979) 
have shown significant correlations between collateral blood flow and infarct size in 
dogs, while Cohen and Yipintsoi (1979) have demonstrated a protective effect of the 
developed collaterals on myocardial function (in this case cardiac failure, as judged by 
left atrial pressure measurements), when the left circumflex was occluded during 
treadmill running in canines. Recently Yanagisawa-Miwa et al. (1992) demonstrated 
that the intracoronary injection of basic fibroblast growth factor improved cardiac 
systolic performance and reduced infarct size in a canine experimental myocardial 
infarct model. There is little available evidence for such correlations or improvements 
of cardiac function following acute coronary artery occlusion in baboons.
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Since limitation of infarct size in the baboon model has been shown to be dependent on 
early reperfusion (Vatner et al. 1987), the sparse early collateralization after coronary 
occlusion in baboons may explain the failure of many pharmacological interventions to 
reduce infarct size in these primates (Geary GG et al. 1982, Geary et al. 1983; 
Flameng et al. 1986; Vatner et al. 1987). Thus any intervention which may improve 
collateralisation in baboons might be expected to improve ventricular function, reduce 
infarct size or to have a synergistic action on the positive effects of other intervention 
agents during the primate myocardial ischaemia or infarction.
Human ischaemic heart disease subjects with well developed collaterals show less 
necrosis, less depressed heart function and longer survival times following myocardial 
infarction (Williams et al. 1976): It is generally accepted that; in humans, coronary 
collaterals are developed in the presence of ischaemia and myocardial infarction; that 
this process of collateralisation is complete within two to four weeks following 
significant coronary occlusion; and that these coronary collaterals help to preserve the 
functional integrity of the myocardium in those hearts with coronary obstructive 
coronary disease (Cohen, 1985; Fujita et al. 1988).
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2.3 SEROTONIN AND THE CARDIOVASCULAR SYSTEM.
2.3.1 INTRODUCTION: THE SEROTONIN MOLECULE.
Serotonin (Five-Hydroxytryptamine, 5-HT) was first recognised in 1949 as a 
vasoconstricting agent. Serotonin is a monoamine, vasoactive peptide (Figure 2.1; page 
16) synthesised in the amine precursor uptake and decarboxylation enterochromaffin 
cells (APUD cells) of the gastro-intestinal tract. Important quantities of this monoamine 
are found in the plasma, platelets and serotonergic neurons of the central nervous 
system and gastro-intestinal wall (Houston and Vanhoutte, 1986).
Serotonin crosses the blood-brain barrier poorly; the serotonin located within the central 
nervous system is synthesised locally. Central serotonergic pathways are involved in 
the regulation of blood pressure (Kuhn et al. 1980). Free plasma serotonin is actively 
taken up and stored in platelets, and destroyed by the liver and vascular endothelial 
cells (by monoamine oxidase). The rapid removal of serotonin by endothelial cells 
makes serum assays of this hormone difficult. This fact makes it more likely that the 
cardiovascular effects of serotonin predominate at discrete sites where platelet 
aggregation occurs, rather than by contributing towards the overall homeostasis of the 
cardiovascular system.
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Figure 2.1: The molecular structure of Serotonin.
CioHiaN20.(COOH)2
Serotonin
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2.3.2 SEROTONIN RECEPTOR THEORY AND SEROTONIN ANTAGONISM.
2.3.2.1 SEROTONIN RECEPTOR THEORY.
The nomenclature of 5-HT peripheral receptors has recently been re-classified using 
several new available serotonin antagonists. The antagonists have also allowed a more 
specific descriptive profile of serotonin binding sites (Janssen, 1983; Bradley et al. 
1986; Leff and Martin, 1988; Chester et al. 1990):
Functional peripheral serotonin receptors are divided into three classes; 5-HT!-like 
receptors, 5-HT2 receptors and 5-HT3 receptors (Bradley et al. 1986). The 
nomenclature and pharmacology of 5-HT2 and 5-HT3 receptors is well described 
through the use of selective antagonists. These two receptor types correspond to the 
older nomenclature of "D" and "M" receptors. A number of serotonin’s vascular 
actions are distinct from the effects of 5-HT2 and 5-HT3 receptors, but because selective 
antagonists for these different receptors are not yet available, they are currently 
classified as 5-HTr like receptors.
5-HTj-like receptors have been located on dog endothelial cells where they mediate the 
release of Nitric Oxide, with subsequent smooth muscle relaxation, by stimulating a rise 
in intracellular cyclic GMP (Cohen et al. 1983). A second 5-HTr like receptor has also 
been located on the smooth muscle myocyte, and here it’s relaxation response is 
mediated by a rise in cyclic AMP. A ligand known as GR 43175, which is selective for
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5-HTj-like receptors, has been found to mediate contraction of the dog saphenous vein 
as well as contraction of human isolated coronary arteries, but to a much lesser degree 
than that of the normal maximum artery serotonin response (Angus, 1989). 5-HTr like 
receptors have also been located on cardiac pacemaker cells and central and peripheral 
neurones of different species including humans (Gothert and Schlicker, 1987).
Highly selective serotonin antagonists have led to both the identification and localisation 
of the specific 5-HT2 receptor. The diverse list of the responses to 5-HT2 receptor 
stimulation includes vasocontraction, platelet aggregation and neuronal depolarisation; 
the receptor is located on vascular smooth muscle myocytes, platelet membranes and 
noradrenergic nerve endings, as well as in the human cortex (Schutte et al. 1983). 
Since my study was specifically concerned with antagonism of 5-HT2 receptors, the 
other known actions of 5-HT2 receptors are summarised in Table 2.1; page 21.
Gothert et al. (1987) have located 5-HT3 receptors on peripheral and central neurones 
of different species including humans, while Kaumann (1985) has named certain porcine 
sino-atrial and left atrial receptors as 5-HT3. The introduction of more specific 
antagonists for 5-HT4 receptors has led to the recent acceptance of their existence 
(Bockaert et al. 1992), and their localisation at specific sites in different species: They 
are found on neurones of the mouse, guinea pig and rat; the guinea-pig ileum plus 
ascending colon and the rat oesophagus, and the human right atrium and ventricle 
(Kaumann, 1985).
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The wide intra- and inter-species variation of the density, types and localisation of 5- 
HT receptors has led to a hypothesis of the possible cellular regulation of 5-HT 
receptors (Leff and Martin, 1988). Serotonin receptors have not been extensively 
studied in primates and have not been studied at all in baboons to date.
2.3.2.2 SEROTONIN ANTAGONISM.
Commonly used agonists at 5-HTj and 5-HT2 receptors are serotonin, spiroperidol and 
lysergic acid. The classical serotonin antagonists are methysergide, metergoline, 
mianserin, cyproheptadine and spiperone. Methysergide is a mixed receptor agonist- 
antagonist. More recently, a compound R41468 known as ketanserin was found to bind 
selectively to 5-HT2 receptors (Janssen, 1985). The structure of ketanserin and certain 
other selective 5-HT2 antagonists is shown in figure 2.2; page 23. The side chains of 
all these compounds end in common typical heterocyclic structures. Ketanserin is the 
most selective of these compounds, being almost devoid of dopaminergic activity.
Ketanserin is a potent, highly selective and competitive 5-HT2 serotonergic receptor 
antagonist. The compound is a piperidine derivative substituted in position 4: (3-(2-(4- 
(4-fluorobenzoyl)-l-piperinyl)ethyl-2,4(iH,3H)-quinazolinedione:The molecular weight 
= 395, but with tartrate, the injectable form, the molecular weight = 545). Ketanserin 
does not bind to 5-HT! receptor sites at all, but has measurable affinity for Hr  
histaminergic, a,- and a 2-adrenergic and D2-dopaminergic (low affinity) binding sites. 
Ketanserin is devoid of agonistic properties (unlike methysergide) and is a potent and
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selective antagonist of the effects of serotonin on the vasculature smooth muscle and 
on platelets. Ketanserin also acts as an anti-hypertensive agent in some species 
including humans (Van Oene, 1990), either by serotonergic blockade or by it’s weak 
a !-blocking properties (Andren, 1983; Janssen, 1983).
LY 53857 (Eli Lilly Co.) is a highly selective and potent central and peripheral 
competitive 5-HT2 receptor antagonist, and has recently been used by several 
researchers as a 5-HT2 blocker (Fuller and Snoddy, 1979; Cohen et al. 1983; Eidt et 
al. 1989; Simpson et al. 1991). This agent has an approximately 300 000 fold lower 
affinity for or-adrenergic receptors than for 5-HT receptors. Although this affinity is an 
advantage over ketanserin because no anti-hypertensive effects are evident, LY 53857 
is a less potent 5-HT2 antagonist, has a relatively short plasma half-life of 30 minutes 
and is not as yet suitable for oral administration (Cohen et al. 1983).
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TABLE 2.1: 5-HT2 RECEPTOR RESPONSES TO SEROTONIN
IN VARIOUS SPECIES.
(Adapted from Bradley et al. 1986)
Responses to 5-HT Species/location Specific antagonism by ketanserin or 
methysergide
In vitro 
Contraction of 
vascular smooth 
muscle
Rabbit aorta Apperley, Humphrey and Levy (1976); 
Feniuk et al. (1985a)
Rat tail artery 
Dog gastrosplenic v.
Bradley, Humphrey and Williams (1985); 
Van Nueten et al. (1981); Van Nueten et al. 
(1981)
Contraction of 
extra-vascular 
smooth muscle
Guinea-pig trachea 
Rat uterus 
Guinea-pig ileum 
(atropine treated)
Van Nueten, Leysen, Vanhoutte and Janssen 
(1982)
Ichida et al. (1983)
Engel et al. (1985)
Platelet aggregation Cat
Rabbit and man
De Clerck, Xhonneux, Leysen and Jannsen (1984) 
No data
In vivo
Vasopressor responses
Pithed/anaesthetized rat Van Nueten et al. (1981);
Feniuk, Humphrey and Perren (1982); 
Fozard (1982)
Saxena and Lawang (1985);
Conscious rat Dalton et al. (1985)
Bronchoconstriction Anaesthetized cat 
Anaesthetized guinea-pig
Reiche and Frey (1983); 
Connor et al. (1986) 
Saxena and Lawang (1985)
5 -Hydroxy tryptophan- 
induced heat twitch
Conscious rat/mouse Malick, Dosen and Barnett (1977)
Oedema Rat paw Ortmann, Bischoff, Radeke Buech and Delini- 
Stula (1982)
Urinary bladder 
contraction (second 
phase)
Anaesthetized cat Saxena, Heiligers, Mylecharane and Tio (1985a)
Figure 2.2: Structural formulae of certain serotonin 5-HT2 
receptor antagonists (Janssen, 1989).
K e t a n s e r i n
( R 4 H 6 8 )
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2.3.3 SEROTONIN AND THE VASCULATURE.
2.3.3.1 INTRODUCTION.
Some of the diverse cardiovascular effects of serotonin include: -
(Houston, 1986; Houston and Vanhoutte, 1986; Reneman and Bollinger, 1986).
Displacement of noradrenaline from adrenergic nerve endings (at high 
concentrations of serotonin), with a subsequent positive chronotropic and 
inotropic (/5X) myocardial effect.
Inhibition (at a pre-junctional site) of vascular sympathetic nerves.
Alteration of blood rheology (thereby adversely affecting the blood’s flow 
properties); a decrease of in vitro filterability, increased vascular permeability 
and a decreased red cell pliability (Dormandy, 1986).
Activation of platelets and the potentiation of other platelet aggregating agents 
and vasoactive agents: Serotonin-induced platelet activation stimulates the release 
of Thromboxane-A2 (and it’s metabolites), as well as stimulating further platelet 
serotonin release via a platelet 5-HT2 receptor. The effect of this is an escalation 
in plasma serotonin concentration,the resulting concentration of which is 
sufficient to act on endothelial cells, myocytes and adrenergic nerve terminals. 
Since platelet aggregation and the release of clotting cascade activating factors 
is a function of thrombus formation, serotonin also plays an important role in
haemostasis.
25
Regulation of intravascular blood flow and blood pressure: Serotonin has direct 
and indirect vasodilator and vasoconstrictor effects: (see ensuing chapters).
2.3.3.2 SEROTONIN AND THE PERIPHERAL VASCULATURE.
Serotonin exerts a consistent vascular contractile response in a variety of isolated 
peripheral vascular preparations. In contrast to this, the in vivo response to serotonin 
is one of both large artery segment constriction and vasodilation of the muscle 
microvasculature, with a net increase in blood flow (Figure 2.3; page 28).
Blackshear et al. (1985), using angiography and blood flow measurements of canine 
femoral arteries in vivo, demonstrated that intra-arterial serotonin reduced the canine 
large artery cross-sectional area by 50% or more, whilst concomitant arteriolar 
dilatation led to a net increase in regional blood flow. They further went on to show 
that this serotonin-induced large artery contraction was inhibited by methysergide and 
ketanserin, thereby implicating the 5-HT2 receptor as that responsible for the 
vasoconstrictor effects of serotonin. The use of selective 5-HT2 blockade also failed to 
block serotonin-induced increments in blood flow in their experiments. Thus 5-HT2 
antagonists may antagonise large vessel constriction caused by serotonin, while still 
permitting serotonin’s vasodilatory responses to occur.
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The above findings led researchers to look at the effects of serotonin and serotonin 
antagonism on the peripheral circulation and on collateral formation in arterial disease 
such as occlusion (Figure 2.3; page 28). Orlandi et al. (1984) found that, following 
superficial femoral arterial ligation in dogs, a 5-HT2 receptor-dependent mechanism 
mediated decreases in the perfusion of the regions served by collaterals (contrary to the 
in vivo unligated normal artery response to serotonin). Heistad (1984) demonstrated that 
atherosclerotic monkeys were supersensitive to the vasoconstrictor effects of serotonin 
when compared with controls: In diseased limbs the large artery constrictor effect of 
serotonin became dominant, resulting in a fall of the hindlimb blood flow. Imhoff 
(1961) was the first to show that when ligation of the infra-renal aorta was combined 
with thrombus formation in cats, the local collateral circulation blood flow was severely 
reduced. Schaub et al. (1976, 1977) confirmed these findings on the feline hindlimb 
collateral circulation, further showing that serotonin depresses collateral blood flow, 
and that this collateral inhibitory effect could be partially reversed by pre-treatment 
with cinanserin (a serotonin antagonist). Nevelsteen et al. (1984) then produced an 
acute obstruction of the cat aorta and found that daily i.p. pre-treatment with ketanserin 
led to a significant improvement in the blood flow and a decrease in the collateral 
vascular resistance of the ischaemic area at risk, thereby further implicating the role of 
5-HT2 receptors in the inhibition of collateral circulations.
In summary, the development of collateral arterial blood vessels appears to be sensitive 
to inhibition by serotonin.
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Figure 2.3: The normal and the pathological in vivo peripheral vascular 
responses to an intra-arterial serotonin infusion.
Normal P a t h o l o g i c a l
Blood Flow-- 
Increased
Blood Flow- 
Decreased
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Figure 2.4: Serotonin’s vascular modes of action; see text 
for explanation. (Vanhoutte, 1987)
F a c i l i t a t i o n  of 
p l a t e l e t  a g g r e g a t i o n
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2.3.3.3. THE MECHANISM OF SEROTONIN’S VASCULAR ACTION.
(Figure 2.4; page 30)
The association of arterial thrombus formation with the inhibition of collateral 
circulation development is possibly linked by the release of serotonin derived from 
activated platelets, when they undergo aggregation during the formation of thrombi. 
The presence of platelet cell membrane-associated 5-HT2 receptors is well documented 
(Amout et al. 1985; De Clerck and Xhonneux, 1985; De Cree et al. 1985; Buhler et 
al. 1987). The action of serotonin at these receptors is to enhance platelet aggregation 
and to mediate further release of serotonin; ketanserin has been shown to inhibit these 
effects.
The vasoconstrictor influence of serotonin is primarily via it’s direct action on 5-HT2 
receptors located on vascular smooth muscle myocytes. In addition, serotonin causes 
displacement of noradrenaline from adrenergic nerve terminals and potentiates the 
action of other vasoconstrictors such as histamine, noradrenaline, angiotensin II, 
thromboxane-A2 and prostaglandin-F2o! (Figure 2.4; page 30).
Serotonin-mediated vasodilation occurs by the release of an endothelial derived relaxing 
factor (EDRF, ? nitric oxide) from endothelial cells which incorporate 5-HTj receptors 
(Cocks and Angus, 1983; Cohen et al. 1983), as well as by a direct action on smooth 
muscle cells incorporating an as yet unidentified 5-HT receptor (Housten and 
Vanhoutte, 1986; Janssen, 1983). Other possible mechanisms of serotonin’s
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vasodilatory effect include; direct pre-junctional adrenergic nerve inhibition, /3- 
adrenergic receptor stimulation, and the activation of inhibitory autonomic nerves with 
the release of vaso-active intestinal polypeptide (Reneman and Bollinger, 1986; 
Vanhoutte, 1987).
2.3.3.4 SEROTONIN AND THE CORONARY CIRCULATION.
(i) CORONARY ARTERY RESPONSES TO SEROTONIN.
The effects of serotonin on the baboon coronary circulation have not been extensively 
investigated, however numerous studies have been performed on other species’ 
coronary circulations, in particular that of the dog. As early as 1982 Brazenor and 
Angus, using an in vitro model, demonstrated that ketanserin could inhibit serotonin- 
induced canine coronary circumflex constrictor activity. Since that time the role of 
serotonin in the coronary circulation has become topical and serotonin was shown to 
be a potent in vivo coronary artery constrictor in anaesthetized dogs (Perez et al. 
1983). Chu and Cobb (1987) then described the effect of serotonin on the proximal 
circumflex arteries of awake dogs as one of a biphasic motor response, characterised 
by initial vasodilation (mediated through the endothelium) followed by delayed 
vasoconstriction.
The typical response to experimental canine coronary stenosis is the development of 
episodic spontaneous decreases in coronary blood flow, interrupted by restorations of
33
blood flow, in the portion of the artery proximal to that site of stenosis. This 
phenomenon has been termed cyclic flow variation (CFV) and is thought to be related 
to platelet aggregation at the sites of stenosis. Serotonin is capable of initiating such 
flow variations and ketanserin has been noted to abolish the existing CFV’s in canines 
(Bush et al. 1984; Apprill et al. 1985; Ashton et al. 1986; Bush, 1987; Ashton et al. 
1989). In one study of canine experimental thrombolysis, following thrombotic 
coronary occlusion and the production of CFV’s, spontaneous arterial re-occlusion was 
found to be promoted by the presence of serotonin and delayed by the presence of 
Thromboxane-A2 and 5-HT2 receptor antagonists (Golino et al. 1988). The vasospasm 
found following coronary artery balloon angioplasty has also been illustrated to be 
reduced by the 5-HT2 receptor antagonist LY 53857 in rabbits (Sigal et al. 1991).
It has been shown that the concentration of serotonin at sites of canine experimental 
coronary occlusion is elevated (Ashton et al. 1986). Benedict et al. (1986) correlated 
coronary sinus plasma serotonin concentrations with in vivo platelet aggregation, during 
canine coronary thrombus formation. It has been noted subsequently that serotonin is 
released into the coronary circulation in increased amounts in patients with coronary 
artery disease (Van den Berg, 1989).
Most coronary-circulation serotonin-related studies have concentrated on coronary 
diameter changes rather than on coronary blood flow or regional myocardial blood flow 
changes: Myocardial blood flow (using a microsphere technique) has been noted to 
increase in the presence of ketanserin after canine coronary artery stenosis and this was
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related to a decline in the cyclic flow reductions of blood flow in the ketanserin group 
(Bush et al. 1984). In addition, using the Langendorff technique and manual coronary 
flow measurements, Luscher et al. (1986) exhibited serotonin-induced reductions of 
coronary flow in the isolated heart of the spontaneously hypertensive rat.
Ruocco et al. (1988), using the radioactive microsphere technique, established that 
serotonin had no effect on the regional myocardial blood flow of pigs unless there was 
a severe coronary stenosis; under the latter condition infused exogenous serotonin 
caused a modest impairment of endocardial blood flow. In primates, coronary artery 
cross-sectional area and blood flow were measured using angiography and doppler 
techniques by Golino et al. (1991); they concluded that serotonin has a vasodilating 
effect in humans with normal coronary arteries but a vasoconstrictor effect, which was 
alleviated in part by ketanserin, in patients with ischaemic heart disease.
(ii) SEROTONIN’S INTERACTION WITH THE VASCULAR ENDOTHELIUM.
One might expect that the normal serotonergic-mediated vasodilator response would be 
blunted in states of coronary artery disease such as occlusion or atherosclerosis, because 
in such pathology the endothelium lining the arteries and arterioles would be damaged. 
Consequently, most serotonin-related coronary studies have concentrated on the 
coronary circulation in the presence of arterial disease of various species:
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Vascular endothelial damage has the effect of:
1) Promoting platelet aggregation and thrombus formation (and consequently the 
release of increased amounts of platelet-stored serotonin).
2) Decreasing serotonin breakdown by endothelial monoamine oxidase.
3) Enhancing the vascular myocyte 5-HT2 receptor exposure to circulating 
serotonin and accordingly encouraging vasoconstriction.
The expected response of coronary endothelial damage on serotonin’s vasoconstrictor 
responses has been investigated. Cocks and Angus (1983) found that both serotonin and 
noradrenaline were more powerful vasoconstrictors in the absence of endothelium in 
pig and dog isolated coronary arteries, following mechanical removal of the 
endothelium. Accordingly, Lamping et al. (1985) and Chu and Cobb (1987), using in 
vivo models of anaesthetized and awake dogs respectively, established that mechanical 
disruption of the coronary artery endothelium potentiated the constrictor response to 
intracoronary infusion of serotonin. These findings were expanded by Shimokawa et 
al. (1987) who illustrated that the ability of porcine coronary arteries with a regenerated 
endothelium (following mechanical denudation) to evoke endothelium dependent 
relaxation, in response to serotonin in vitro, was reduced; the morphology of the 
regenerated endothelial cells was different from that of the native non-denuded cells. 
Moreover, Nyborg and Mikkelsen (1988) looked at the effects of aging on rat coronary 
resistance arteries and noted that with increasing age the coronary vascular constrictor 
response to infused serotonin was elevated.
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(iii) CONCLUSION.
In summary, some of the possible advantages of blocking the effects of serotonin at 
coronary 5-HT2 receptors in the presence of coronary artery occlusive disease may be; 
decreased platelet aggregation and thrombus formation; 
decreased platelet activation and reduced additional platelet serotonin release; 
decreased serotonin-mediated vascular myocyte contraction;
decreased serotonin-mediated inhibition of the developing coronary collateral 
circulation.
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2A METHODS OF REGIONAL AND COLLATERAL
MYOCARDIAL BLOOD FLOW MEASUREMENT.
2.4.1 TECHNIQUES OF COLLATERAL CIRCULATION MEASUREMENT.
Numerous direct and indirect measurements of the collateral circulation have been 
employed by different researchers over the past two decades. Studies of the collateral 
circulation require the measurement of both coronary pressures and blood flows, and 
their changes over time. No single used method is ideal. Schaper et al. (1965, 1988) 
and Cohen (1985) have experimented with and reviewed the usefulness of several of 
these methods:
Direct visual techniques of assessing collaterals encompass the exploitation of both 
histology and arteriography (coronary angiography). Both of these techniques involve 
the counting and the grading according to size of visualised collateral anastomoses. The 
histology methods are time-consuming and give no assessment of either temporal 
fluctuation or functionality of the collaterals. The angiographic assessments often do not 
offer sufficient definition for quantification of collaterals, since many collaterals are 
microscopic in size and are located subendocardially. In addition, it is well known that 
a significant pressure gradient across a collateral network is a prerequisite for the 
angiographic visualisation of coronary collaterals (Fujita et al. 1988). The use of 
traditional coronary cineangiography also has inherent problems relating to; the 
discordance of anatomy and functionality of the vasculature; limitations of the X-ray
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imaging chain (such as the maximum obtainable speed of successive exposures); 
operator experience, and the biological characteristics of the animal under surveillance 
(Verani, 1983; Theron et al. 1991).
A system of cannulating the coronary artery distal to the site of occlusion, and 
measuring the rate of blood flow through this cannula, gives an assessment of 
"retrograde flow". This technique has been used as an index of collateral flow, however 
retrograde flow has often been shown to be either greater than or less than actual 
collateral blood flow. The discrepancy noted is due to factors such as ongoing venous 
drainage due to retrograde venous blood flow, or differences in the resistance to blood 
flow of the cannula used versus that of the original coronary artery.
"Peripheral coronary pressure" is another indirect collateral index that refers to 
intracoronary pressure distal to a site of coronary occlusion. The principle behind this 
method, first used by Schaper et al. (1965), is that an increased collateral blood flow 
results in a greater filling of the vascular bed at risk, and hence a higher residual distal 
arterial pressure (in the absence of anterograde flow). The measurement is unreliable 
since peripheral coronary pressure is also related to changes in left ventricular pressure, 
ventricular wall tension and aortic blood pressure.
Another two methods which have been employed as indices of the collateral circulation 
are the myocardial clearance of inert gases (the time taken for washout of injected 
gamma-isotopes), and the myocardial uptake of isotope potassium analogues (blood
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flow is reflected by the supply of the tracer to the myocardium and hence myocardial 
uptake of this tracer). Rapid uptake of inert gases by pericardial fat results in tailing 
off of the washout curve, which can affect blood flow determinations, whilst the 
potassium analogue is lost from ischaemic and normal myocardium at different rates, 
interfering with blood flow determinations as a function of time.
2.4.2 THE RADIOACTIVE MICROSPHERE TECHNIQUE.
2.4.2.1 HISTORICAL BACKGROUND.
Because of the technical and theoretical problems which arise when using the above- 
mentioned assessments, the technique of utilising radioactive microspheres to measure 
blood flow has gained much popularity and acceptance in the field of circulation 
research. Collateral flow can be measured reliably and reproducibly when using this 
tracer technique if the right precautions are taken. As a result, radioactive microspheres 
are generally thought to be the best form of measurement of the collateral circulation.
In 1967 Rudolph and Heymann first described a successful technique of measuring the 
distribution of blood flow using radionuclide labelled 50 /im diameter particles in goats. 
Following their experiments radio-labelled microspheres have become a gold standard 
for regional blood flow measurements in experimental animals. The microspheres are 
nowadays composed of an inert, insoluble carbonized plastic, and range in size from 
1 to 100 /urn in diameter. Nen-Trac spheres (NenR) are labelled with one of 7 possible
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gamma nuclides, and two beta emmiter nuclides, which nuclides are incorporated into 
the microsphere plastic. The density of the plastic microspheres is manufactured to be 
close to that of red blood cells.
The major disadvantages of the microsphere technique are the hazards of the exposure 
of researchers to the radio-isotope and the expense of the radio-isotopes. The 
advantages of this technique over that of others is that the spheres give a measurable 
indication of the amount of blood flowing to the myocardium. As a result regional 
blood flows of various myocardial areas can be determined, furnishing a quantitative 
assessment of myocardial blood flow, transmural blood flow ratios, and a functional 
assessment of vascular collateral formation (Schaper, 1978).
2.4.2.2 TECHNICAL POINTS PERTAINING TO THE USE OF 
MICROSPHERES.
The physical characteristics of microspheres which may affect blood flow determination 
include the size and shape of the spheres, the isotope’s specific activity, radionuclide 
label purity and leaching of the nuclide from the microspheres. Leaching refers to the 
physical loss of radioactive nuclide from the plastic microspheres per unit time.
Microspheres are usually suspended in a solution of either saline or Dextran. Tween-80 
(polyoxyethylene sorbiton mono-oleate, a detergent) is added to the suspension to 
prevent sphere aggregation. Tween-80 in concentrations of greater than 0.05 % may
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affect haemodynamics and the concentration most commonly used is therefore 0.01 % 
(Warren and Ledingham, 1974). Most commercially available microsphere preparations 
meet nuclide leach criteria of less than 1 % leaching in saline over four days, and less 
than 2 % leaching in plasma over 2 days in vitro. The in vivo use of spheres for 
greater than twenty four hours may result in different sphere isotope leach 
characteristics.
Following intravascular injection the microspheres are trapped in arterioles or 
capillaries. In order to establish accurate flow measurements, the spheres must be well 
mixed within the blood stream immediately after injection; uniform distribution of the 
microspheres throughout the cross section of the vessel is important and should 
approximate the normal red blood cell distribution (Wagner et al 1969). Two factors 
which affect this uniformity of microsphere distribution are the site of the spheres’ 
injection and the number of microspheres injected. The best possible site for injection 
is that which is most proximal to an organ under consideration since this allows the 
greatest time for sphere mixing to occur in the bloodstream prior to entering the 
organ’s vascular bed. Hence, if accessible, the left atrium should be preferentially used, 
particularly in studies involving the coronary circulation.
After the experiment a comparison of the number of microspheres per gram of tissue 
in the left and right cerebral hemispheres or kidneys gives an indication of the evenness 
of sphere distribution within the blood stream. Alternatively, bifemoral blood samples 
can be withdrawn simultaneously and their radioactive counts compared. It is shown
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that the number of microspheres per sample of tissue being counted should number 
around 400 in order to have a distribution variability of within 10 % of the mean 
distribution (Buckberg et al. 1971).
The number and size of microspheres per injection, and the frequency of different 
injections may also have an effect on haemodynamics. In general, depending on the 
animal species used, the repeated intra-arterial injection of 300 000 to 500 000 15/xm 
diameter spheres causes no significant acute or chronic haemodynamic alterations. The 
number of spheres applied per injection must obviously be reduced when using spheres 
of larger diameters, since the degree of obstruction of the microcirculation is related 
to the diameter of vessels obstructed. In smaller animals fewer microspheres are used 
even if small diameter microspheres have been selected.
The physical size of the microspheres affects both the myocardial entrapment of spheres 
and the site of entrapment. Large diameter spheres of 50 have been noted to 
preferentially precipitate out in the subendocardial layers of the dog heart (Kaihara et 
al. 1969). In addition, the diameters of capillaries and arteriovenous anastomoses may 
vary between different organs and between animal species, thus affecting the site of 
sphere entrapment as well as the number of spheres trapped. An alteration of 
physiological conditions such as temperature, or the use of anaesthetic agents may 
affect microsphere entrapment. The in vivo time-related loss of microspheres previously 
trapped in tissue has also been documented (Crystal et al. 1979). The degree of sphere 
entrapment can be assessed by measuring the microsphere activity of that organ’s total
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venous drainage, or by counting the activity of organs which receive that venous 
drainage.
In general, 15 nm diameter microspheres satisfy the conditions of having a vascular 
distribution similar to that of red blood cells, the absence of significant non-entrapment 
and a lack of haemodynamic effects.
2.4.2.3 TECHNICAL POINTS PERTAINING TO THE ADMINISTRATION OF 
MICROSPHERES.
Prior to left atrial injection the spheres must be agitated by vortexing and 
ultrasonication in order to reduce sphere clumping and aggregation. The absence of 
significant aggregation is confirmed microscopically. Attention to sterility is important 
in animal survival experiments and the ultrasonication proves to be useful as a 
bactericidal means. Spheres are drawn up into a teflon-coated or glass syringe and 
injected via the left atrial cannula over 10 or 20 seconds, after which the cannula is 
flushed with 10 ml of saline over 10 or 20 seconds. The solution of spheres for 
injection should be warmed to body temperature to reduce the incidence of thermal- 
related ventricular ectopy. In the author’s experience, the ultrasonication of the 
microsphere vial alone usually results in an adequate rise of the injectate’s temperature.
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If calculations are made based on the total number of microspheres injected (such as 
for cardiac output determination), caution must be taken to ensure that there is no loss 
of microspheres during the injection procedure and the left atrial cannulas should also 
be counted for residual radioactivity. In addition, the time difference between the 
counting of the spheres injected and the counting of the reference blood samples and 
tissue blood samples should be accounted for using the known radioactive decay 
constants of the different isotopes as follows;
CALCULATION OF RADIOACTIVE NUCLIDE DECAY:
let Cj = the sample’s counts per minute (cpm) at time t0. 
let c,/2 = the sample’s cpm at time t,.
let ti - t„ = x = the known half-life (T) of the isotope, in days, 
let y = the number of cpm which have decayed in time x.
then,
y = ln(Cj) - ln(C|/2), where In = natural logarithm.
and
dy/dx = (ln(c,) - ln(c1/2))/(tj - 1„) = In2/T = 0.693/T
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Therefore,
For any given time difference (t), the original cpm (O) of a given sample’s currently 
measured cpm (M) is calculated from:
Q  _  gln(M) + (0.693/T).t
2.4.2.4 CALCULATION OF BLOOD FLOW.
(i) METHOD OF TISSUE SAMPLE COUNTING.
It is important to procure similar geometry of the prepared samples because geometry 
(sample height, volume, density and composition) affects the radioactive counts 
obtained (Heymann et al. 1977). Glass and plastic containers attenuate the counts 
differently, so the counting vials must all be of the same type. The myocardium is cut 
up to facilitate packing of tissue into the vials and the tissue must occupy the same 
height in each vial. After the sample weights have been determined, the tissue can be 
counted in a wet or carbonized form. In the author’s experiment, the technique of 
dissolving the myocardium in nitric acid (after packing the tissue into the counting 
vials) was used: The result of tissue degradation by nitric acid causes the release of 
spheres from tissue, and the spheres settle out at the bottom of the counting vial.
46
Samples are counted in a gamma-scintillation counter or multi-channel pulse-height 
analyzer using window-spectrometry, according to the types of isotopes used. The 
energy range which is selected for the counting of each isotope is also an important 
determinant of the final counts obtained: Different isotopes tend to have different 
energy spectrum peaks and this fact is exploited to obtain energy range windows with 
a high specificity for each isotope. Ideally, the energy spectrum that is selected for each 
isotope should extend from the centre of the pre-photoelectric-peak trough to as close 
to the background count as possible on the high energy side of the peak. The 
advantages of choosing a wide window for each isotope (higher counting efficiencies) 
are offset by the greater overlap (or lesser separation) of the different isotopes’ energy 
spectra.
Samples are counted over the entire energy spectrum as well as in their respective 
window ranges simultaneously. All samples are counted on the same day, but a 2 or 
3 day difference is, depending on the isotope used, usually insignificant. The duration 
of sample counting-time is dependent on the various activities of the isotopes used: The 
greater the activity of an isotope the better is the counting efficiency of the gamma- 
counter, and the less is the time that is needed to be spent on counting the tissue 
sample; in the author’s experiment, a 10 minute count, repeated once (and the mean 
of the two counts taken) was used for each tissue sample.
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(ii) ANALYSIS OF COUNTS.
Calculation of regional blood flow can be performed in two ways: Cardiac output can 
be measured by an independent means, in which case the individual organ flow derived 
from the proportion of microspheres found in that organ is related to either the total 
number of spheres injected or to the total number of spheres present in the whole 
animal (the latter method is obviously not practical in large animal studies).
The second technique requires the measurement of flow to one organ by an independent 
means; flow to any organ can then be calculated from the formula:-
Q = (Z x M)/N
Where Q = Unknown organ flow in ml.min'1 
Z = Known organ flow in ml.min'1
M = Number of microspheres in organ with unknown flow 
N = Number of microspheres in organ with known flow
Currently, the most commonly employed method to obtain "Z" and "N" is that of 
knowing a surrogate organ’s flow. This is acquired by exploiting the "reference sample 
technique" which involves the withdrawal of blood from an artery at a constant rate
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using a (Harvard) withdrawal pump. The blood withdrawal is started 10 seconds prior 
to the injection of the spheres and is continued for usually 1 - 2  minutes. (In the 
author’s experiment the blood was withdrawn from the aorta over an average period 
of 2 minutes).
After the blood withdrawal the syringe is weighed and the volume of blood that is 
withdrawn, and hence the reference blood flow rate, is calculated by using the 
formula:-
Z = ((WB2 - WB1)/DB)(60/S)
Where;
Z = The rate of the reference blood sample withdrawal, in 
ml.min'1
WB, = The measured weight of the syringe prior to blood 
withdrawal, in grams.
WB2 = The measured weight of the syringe after the blood 
withdrawal, in grams.
Db = The known density of blood.
S = The time of withdrawal, in seconds.
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The blood is then placed into counting vials with care being taken to flush the glass 
withdrawal syringe using distilled water to ensure that no spheres are left adhering to 
the syringe sides. A flow rate ("Z") of 8 - 12 ml.min'1 is usually sufficient to ensure 
that the spheres do not adhere to the suction tubing during the withdrawal procedure.
In large animals, more than one reference sample may be withdrawn simultaneously for 
purposes of comparing the spheres’ mixing uniformity and to improve on the precision 
of the technique.
(iii) SPECTRAL DISTRIBUTION STRIPPING.
When using more than one isotope to determine regional myocardial blood flows the 
background count and the count due to other isotopes’ energy emission must be 
p [ u A s T  1 0 1 4 b 3 s
percentage of counts found in the windows of the other isotopes which were used is 
noted. This is performed by counting either a pure nuclide sample or by making use 
of the counted reference withdrawal blood sample (Table 2.2, page 50);
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Energy Range: 
(KeV)
0-450 (113Sn) 460-690 (85Sr) 700-2000 (46Sc)
Percentage count 
of total energy 
spectrum 
occupying each 
window:
H
F E
C B A
Table 2.2
For the nuclide with the highest energy range peak (Sc):
Let K1 = measured counts per minute (cpm) of the Sc tissue sample in 
the chosen Sc window.
Let LI = measured cpm of the Sc reference blood sample, in the chosen 
Sc window.
and,
Let total measured tissue sample Sc activity over the entire energy 
spectrum = M l.
Let total measured reference blood sample Sc activity over the entire energy
spectrum = N l.
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M l = Kl/A ( A is derived from Table 2.2 and expressed as a 
decimal).
and
N1 = Ll/A
Therefore,
Q1 = (Z1.M1.100)/(N1.W1)
Then,
Where
Q1 = Unknown tissue sample flow of Sc nuclide, in ml/min.lOOg 
Z1 = Known reference sample flow rate, in ml.min'1 
W1 = Mass of tissue sample with unknown flow, in grams.
Similarly, fo r  the nuclide with the second highest primary energy range peak (Sr):
M2 = (K2/E) - ((B.MU/E)
N2 = L2/E
Q2 = (Z2.M2.100)/(N2. W2)
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Similarly, fo r the nuclide with the lowest primary energy range peak (Sn):
M3 = (K3/H) - ((F.M2 + C.M1)/H) 
N3 = L3/H
Q3 = (Z3.M3.100)/(N3.W3)
Thus the absolute counts of each isotope in their respective windows is determined, and 
the tissue sample flows are calculated using the above equations. Note that this 
calculation assumes that each isotope has little forward overlap into the energy ranges 
of the other isotopes which occupy higher energy spectra.
The use of computer software programs makes these calculations very much less time 
consuming, however such commercially available software is often expensive, and a 
simple Basic-Language program written by the author (compatible with DOS Q-Basic, 
GW-Basic and IBM Basic-A) suffices for the above-described calculations (Table 2.3; 
page 55).
(iv) VALIDITY OF THE RADIOACTIVE MICROSPHERE TECHNIQUE.
The distribution of microspheres within the bloodstream and organs correlates well with 
that found using dye-indicator and radioactive potassium-uptake techniques. Cardiac 
output measurements show good correlation with dye indicator techniques however the
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author’s experience is that, unless extremely meticulous measures are taken to ensure 
accurate activity-counts of the injected spheres and of the spheres remaining behind in 
the syringes and cannulas, large errors may be encountered in the estimation of cardiac 
output. Organ blood flows, derived using the microsphere technique, also correlate well 
with those obtained from electromagnetic flow probe measurements or by the direct 
collection of venous effluent (Sasaki and Wagner, 1971; Heymann et al. 1977). An 
attempt was made by Maxwell et al. 1987 to demonstrate that a component of coronary 
collateral flow could not be detected with microspheres; thus the regional distribution 
of blood flow using the microsphere method was compared with several other isotope- 
uptake techniques but the results showed that there was no biologically significant 
microsphere-insensitive component of collateral blood flow in dogs.
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Table 2.3: Authors example of a simple computer program for 
the radioactive microsphere spectral distribution 
stripping technique.
list
20 REM MICROSPHERE CALCULATION
40 PRINT"PROGRAM MICROHART:MAX 3 MICROSPHERES"
45 PRINT"This program may only be copied with written per 
50 PRINT
55 PRINT "Check printer is on line!!"
56 PRINT
60 PRINT"INPUT THE FOLLOWING GENERAL DATA"
80 PRINT
100 INPUT"ENTER ll;cpm blood Sc";Ll 
110 PRINT"11=",LI
120 INPUT"ENTER 12;cpm blood Sr";L2 
130 PRINT"12=",L2
140 INPUT"ENTER 13;cpm blood Tn";L3 
150 PRINT"13=",L3
160 INPUT"ENTER zljblood flow in ml/min Sc";Zl 
170 PRINT"zl=",Z1
180 INPUT"ENTER z2;blood flow in ml/min Sr";Z2 
190 PRINT"z2=",Z2
200 INPUT"ENTER z3;blood flow in ml/rain Tn";Z3
220 INPUT"ENTER a;% energy of Sc occupying Sc range,as a
230 PRINT"a=",A
240 INPUT"ENTER b;% of Sc occupying Sr range";B 
250 PRINT"b=",B
260 INPUT"ENTER c;% of Sc occupying Tn range";C 
270 PRINT"c=",C
280 INPUT"ENTER e;% energy of Str occupying Str range";E 
290 PRINT"e=",E
300 INPUT"ENTER f;% of Str occupying Tn range";F 
310 PRINT"f=",F
320 INPUT"ENTER h;% energy of Tn occupying Tn range";H 
330 PRINT"h=",H 
335 PRINT
340 PRINT"PREPARE TISSUE SAMPLE DATA"
350 PRINT 
360 PRINT
370 INPUT"ENTER R ;THE SAMPLE CODE/NO.";R$
380 PRINT"R=",R
390 INPUT"ENTER the mass of tissue in grams-w";W 
400 PRINT"**",W
410 INPUT"cpm tissue Sc,kl=";Kl
420 PRINT"kl=",K1
430 INPUT"cpm tissue Str,k2=";K2
440 PRINT"k2=",K2
450 INPUT"cpm tissue Tn,k3=";K3
460 PRINT"k3=",K3
470 PRINT
480 PRINT
490 PRINT
500 PRINT"NOW CALCULATING"
510 Ml=K1/A
520 PRINT"ml=",Ml
530 N1=L1/A
540 PRINT"nl=",N1
550 Q1=(Z1*M1*100)/(N1*W)
560 M2=(K2/E)-((B*M1)/E)
570 PRINT"m2=",M2
580 N2=L2/E
590 PRINT"n2=",N2
600 Q2=(Z2*M2*100)/(N2*W)
610 M3=(K3/H)-(((F*M2)+(C*M1))/H)
620 PRINT"m3=",M3
625 N3=L3/H
630 PRINT"n3=",N3
640 Q3=(Z3*M3*100)/(N3*W)
650 PRINT 
660 PRINT
670 PRINT"FOR SAMPLE NO.";R$
680 PRINT
690 PRINT"Sc TISSUE FLOW in ml/min,ql*";Ql
700 PRINT’’Str TISSUE FLOWin ml/min,q2=";Q2
701 PRINT"Tn TISSUE FLOW in ml/min, q3=”;Q3
718 PRINT
719 PRINT"clieck printer is on-line"
720 LPRINT"For tissue sample no.";R$
725 LPRINT " " " " ;"fIow ml/min"
730 LPRINT "Tn/q3” USING ”££££££.£” ;Q3
740 LPRINT "Sc/ql" USING ”££££££.£” ; Q 1
750 LPRINT "Sr/q2” USING "££££££.£" ; <52
760 PRINT 
762 GOTO 370 
770 PRINT
780 INPUT"TO RUN ANOTHER SAMPLE ON THIS SERIES DEPRESS KEY 1,otherwise press anj- 
NUMBER";S
790 IF S = 1 ,GOTO 340,ELSE GOTO 810 
810 STOP
5 REM "BACKGROUND DEDUCTIONS"
10 INPUT”mean blank 210-450?/",A1 
20 INPUT"mean blanks450-690/",A2 
30 INPUT"mean blanks700-2000/",A3 
40 INPUT"mean blanks open A/",A4 
50 INPUT"mean blanks open B/",A5 
60 INPUT"sample no.?/",Z 
70 INPUT"cpml 210/",B1 
80 INPUT"cpml 460/",Cl 
90 INPUT"cpml openla/",Dl 
100 INPUT"2cpm 210/",B2 
110 INPUT"2cpm 460/",C2
120 INPUT"cpm open2a/",D2
121 INPUT"3cpra 210\",B3
122 INPUT"3cpm 460\",C3
123 INPUT"open3a\",D3 
130 INPUT"cpml 700/",El 
140 INPUT"cpm openlb/",Fl 
150 INPUT"2cpm 700/",E2
160 INPUT"cpm open2b/",F2
161 INPUT"3cpm 700\",E3
162 INPUT"open3b\",F3 
170 B4=((Bl+B2+B3)/3)-Al 
180 C4 = ((C1+C2+C3)/3)-A2 
190 E4=((E1+E24E3)/3)-A3 
200 D4=((Dl+D2+D3)/3)-A4 
210 F4=((F1+F2+F3)/3)-A5 
220 G4=(D4+F4)/2
230 PRINT"mean210=",B4 
240 PRINT"mean460=",C4 
250 PRINT"mean700 = ", E4 
260 PRINT"mean open=",G4 
270 LPRINT
280 LPRINT Z"=";CINT(B4),CINT(C4),CINT(E4),CINT(G4) 
290 GOTO 60
300 INPUT"press 1 to cont",W 
310 IF W=1,GOTO 60,ELSE320 
320 STOP 
Ok
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2.5 EXPERIMENTAL PRODUCTION OF MYOCARDIAL 
INFARCTION.
2.5.1 OBSTRUCTION OF CORONARY ARTERIES.
The most logical method of inducing a myocardial infarct in experimental animals is 
to interrupt the myocardial oxygen supply. This interference of coronary blood flow can 
be produced in several ways:
A) In the open or closed chest models: Options are; the closed chest model alone, 
the closed chest model following an open chest, or the open chest model alone. 
The major advantage of the open chest model is the technical ease of animal 
instrumentation. The main disadvantage of the open chest model is the many 
haemodynamic disturbances which may result, thereby influencing the 
interpretation of measured variables. Such haemodynamic disturbances may arise 
from;
(i) A reduced cardiac venous return and hence a reduced right and left sided cardiac 
output. The venous return is reduced by the absence of negative intra-pleural 
and intrathoracic pressures (secondary to mandatory open-chest artificial 
ventilation) and hence a decreased gradient of blood flow between the peripheral 
veins and the right atrium.
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(ii) The necessary supine position of the animal (the normal erect positional effects 
of gravity on venous return are altered)
(iii) The surgical manipulation involved leads to neurohumoral responses such as the 
release of inotropic and chronotropic catecholamines (particularly when 
performing the sternotomy or thoracotomy).
(iv) The opening of the pericardial sac (a change in the viscous properties of the 
fluid surrounding the heart).
(v) Thermal disturbances, resulting from exposure of the thoracic cavity to the 
atmosphere.
(vi) Regional myocardial blood flow disturbances; thoracotomy is known to affect 
the endocardial:epicardial blood flow ratio in dogs (Bishop et al. 1984).
Disadvantages of the closed chest model are;
(i) The difficulty with which interruption of coronary blood flow is achieved.
(ii) The necessary peripheral introduction of the vascular catheters, and their 
associated haemodynamic effects, to record haemodynamic variables.
B) Acute versus chronic interruption of coronary blood flow: Acute ligation of a 
coronary artery usually ensures myocardial infarction, where a chronic 
interruption may give varying degrees of stenosis in the experimental subjects. 
The major advantages of the chronic arterial occlusion method are;
(i) The duration of gradual occlusion resembles more closely that of human
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ischaemic heart disease and hence the experimentally produced pathophysiology 
is likely to be more authentic.
(ii) There is a lower incidence of ventricular fibrillation and other acute ischaemia 
related cardiac arrythmias.
2.5.2 CORONARY ARTERY LIGATION.
The simplest and most widely employed technique of coronary blood flow interruption 
is by ligation of the coronary arteries. This procedure is usually performed with the 
chest open, although a system of placing the ligature around the coronary artery and 
extending the loop through the chest wall in a snare has been used in a closed chest 
model to allow progressive partial arterial occlusion. In most cases ligation is 
performed with silk suture as a one stage procedure but it is feasible to perform a two- 
stage procedure, in which the first ligation is only partial, to reduce the incidence of 
ventricular fibrillation post-occlusion. It is also necessary in certain animal models to 
ligate more than one arterial site to produce an infarct because of the existence of a 
good coronary collateral circulation. In the dog, both the left anterior descending 
(LAD) and the circumflex arteries have been ligated for this reason (Schaper, 1978).
In the baboon acute single vessel ligation produces a well circumscribed infarct, and 
this technique has often therefore been utilised for myocardial infarct studies in these 
primates (Lubbe et al. 1974; Barker et al. 1980; Geary et al. 1981; Flameng et al. 
1986; Flameng et al. 1990). Vessel ligation in the baboon requires careful dissection
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of the coronary artery and the threading of the silk suture beneath the artery prior to 
ligation. Usually the left anterior descending coronary artery (Lubbe et al. 1974), or 
one of it’s large diagonal branches (Geary et al. 1981; Ruf et al. 1986), is chosen as 
the site of ligation .
Different researchers have tied the baboon LAD at various sites;- the junction of the 
distal one third and proximal two thirds of it’s length, the mid-LAD and just distal to 
the first diagonal branch have all been used. In the author’s experience, ligation of the 
distal LAD proves to be technically difficult, particularly in smaller female baboons, 
and may not produce a large enough infarct: On the other hand, ligation of the LAD 
at a site excessively proximal was associated with a very high incidence of ventricular 
fibrillation. Care is taken not to ensnare the adjacent coronary vein in the arterial 
ligation since this may lead to haemodynamic interferences and atypical infarct 
pathology. Acute coronary artery ligation in the baboon results in a well circumscribed 
infarct, with a clearly defined edge (Opie et al. 1983).
2.5.3 ADDITIONAL METHODS OF PRODUCING CORONARY OCCLUSION.
Certain other methods which have been successfully employed (but not in baboons as 
yet) permit closed chest or gradual restriction of coronary arteries (Tillmanns et al. 
1975). Examples are: Chronically implanted balloon cuffs placed around the artery and 
linked to a micro-flow infusion pump; releasable clips; screw forceps and screw clamps 
for gradual occlusion; intracoronary balloon catheters introduced under fluoroscopic
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guidance; techniques which involve the production of coronary thrombosis and 
embolisation (see below), through the use of injected large plastic spheres or metals and 
springs. Experimentally produced atherosclerosis has also been attempted in dogs, rats, 
rabbits and baboons, utilising high cholesterol diets.
Ameroid constrictors can be used to produce gradual coronary occlusion. These devices 
consist of a hygroscopic material (a casein derivative) encased in a rigid silver or 
stainless steel capsule. Once placed around the coronary artery they absorb water and 
constrict the arterial lumen over a gradual period of time (which time period is 
adjustable).
Hydraulic vessel occluders are reported to have been used to study myocardial 
infarction in awake baboons (Crozatier et al. 1978; Vatner et al. 1987).
2.5.4 METHODS OF EXPERIMENTAL ARTERIAL THROMBOSIS.
To simulate the conditions of coronary artery disease found in humans the production 
of a thrombus within an animal coronary artery is imperative. The presence of 
associated thrombi with human myocardial infarction following coronary artery disease 
is very frequent (80- 90 %), and the superimposition of an acute thrombus on a pre­
existing coronary vascular plaque (causing a critical coronary stenosis) is thought to be 
the precipitating event for human myocardial infarction. As previously mentioned 
(section 2.3.3), thrombi contain activated platelets which release vaso-active substances
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(serotonin). These agents can, in turn, influence coronary blood flow and the 
development of coronary collateral circulations.
Techniques to accomplish thrombogenesis in coronary arteries have ranged from the 
introduction of thrombogenic foreign bodies such as metal wires (aluminium, 
magnesium, copper and lead ) to the placement of electrical and thermal intraluminal 
currents across the vessel walls (Tillmans et al. 1975).
As early as 1961, Imhoff recognised the importance of vascular thrombi in the 
pathogenesis of sequelae to vascular occlusion. He pioneered the technique of producing 
an in vivo thrombus in cat aortas by introducing thrombin into an arterial sac, created 
by two aortic ligations; the second ligation was tied at a site approximately 1 cm 
proximal to the first. Schaub et al. (1976) were the first researchers to follow up on the 
work of Imhoff by testing the effects of producing an aortic thrombus in cats on the 
hindlimb collateral circulation. The intravascular thrombus created in their experiments 
was induced using thromboplastin in place of thrombin, but the ligation and arterial sac 
creation techniques used were the same as those of Imhoff. Schaub subsequently made 
further use of this arterial sac technique to look at the effects of serotonin and thrombus 
formation on the feline collateral circulation (Schaub et al. 1977). More recently it has 
been shown that low-dose thrombin activates platelets and causes the release of 
serotonin from in vitro human platelets (Marche et al. 1985).
The method of intravascular thrombus formation using platelet aggregation agents has
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been extended to the coronary circulation (Flameng et al. 1985): Flameng et al. 
produced an occlusive thrombus by thrombin-induced coagulation in the LAD (left 
anterior descending) artery of open-chest baboons, in a study of myocardial infarction; 
after dissection of the LAD a 1 cm length of artery was ligated proximally and distally, 
and approximately 10 u of thrombin was injected into the sac so created. The LAD 
segment was also repeatedly crushed with a small forceps. This resulted in a localised 
thrombus occluding the LAD. The technique was later used again for infarct-size 
studies in baboons. (Flameng et al. 1990).
2.6 METHODS OF DETERMINING INFARCT SIZE.
The demonstration and quantification of an infarct’s size can be performed indirectly 
(techniques usually used in living animals) or directly (post-mortem techniques). 
Indirect techniques include electrocardiographic ST-segment maps, measurements of 
plasma cardiac enzymes such as creatine kinase (De Scheerder et al. 1987), 
radionuclide-uptake ventriculography and echocardiography. The combination of serum 
creatine kinase-MB isoenzyme (CK-MB) measurements and ST-segment mapping has 
also often been used as an index of infarct size (Rogers et al. 1982; Burke et al. 1983; 
Rogers et al. 1983).
Direct infarct size measurements are more definitive, being based on macroscopic 
evaluation or microscopic histology: At the macroscopic level, the interface between
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viable and infarcted myocardium is frequently not sharply defined, particularly if the 
infarct is of recent origin ( 2 - 3  days). Therefore, the dyes para-nitro blue tetrazolium 
(pNBT) and triphenyl tetrazolium chloride (TTC), which are coloured blue or red 
respectively when reduced by viable cardiac tissue’s deydrogenases (such as NADH), 
are used to define the infarct’s boundaries more clearly. TTC, which is less expensive, 
can be applied directly to post-mortem slices after the ventricles are sectioned in 1 - 2 
cm intervals from apex to base. TTC can also be perfused post-mortem or in vivo into 
the myocardium via the coronary arteries (Reimer and Jennings, 1984).
When macroscopically viewed, myocardial infarct size can be quantified following 
ventricular sectioning by planimetry of the ventricle slices and the subsequent 
calculation of area, volume or mass. Although the TTC technique has been used in 
baboons (Flameng et al. 1986), myocardial infarction in the baboon, unlike that of the 
dog, tends to show a clearly defined infarct edge (Lubbe et al. 1974; Crozatier et al. 
1978) and therefore the above staining techniques are unnecessary to delineate the 
baboon’s infarct border.
When assessing the impact of therapeutic interventions on myocardial infarct size, it 
is useful to determine the perfusion bed of an occluded coronary artery, since this 
defines the myocardial area at risk for infarction. If experiments are performed to 
determine the effects of drugs on infarct size, the ratio of infarct size to area at risk is 
more useful than the quantification of infarct size alone. The microscopic techniques 
employed to delineate the perfusion bed of a coronary artery have been used in baboons
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(Geary et al. 1981; Geary et al. 1982; Geary et al. 1983; Flameng et al. 1985; 
Flameng et al. 1986). One of these methods involves the placement of cannulas in the 
LAD proximal and distal to the site of occlusion, in the proximal left circumflex artery 
and in the proximal right coronary artery. Following cannula placement the arteries are 
injected simultaneously, and at equal flow rates, with coloured silicone microvascular 
dyes. Serial cross-sections of the ventricles are then viewed microscopically allowing 
the anatomical areas of perfusion and infarction to be determined by planimetry. The 
disadvantage of the microscopic technique of infarct-size measurement is that it 
precludes the simultaneous use of radio-active tracer microspheres to determine regional 
myocardial blood flows.
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CHAPTER 3: METHODS.
3.1 EXPERIMENTAL MODEL.
A total of twenty seven baboons underwent surgery, of which twelve were excluded 
from the final analysis due to mortality or morbidity. Permission to perform the 
experiments was granted by the University of the Witwatersrand Animal Ethics 
Screening Committee (AEC No.’s 89/176/5 and 90/15/5). Fifteen female baboons 
(Papio ursinus) weighing 19.3 ±  1.2 kg were anaesthetized and subjected to coronary 
artery ligation. Nine of the animals received ketanserin tartrate (Janssen Pharmaceutica) 
1 mg/kg i.m. and six received the vehicle i.m. (injectable water) 24 hours pre- 
operatively and daily at 0800 hours thereafter. Haemodynamic variables were recorded 
and radioactive microspheres were injected in the open chest model before and after 
coronary artery ligation. All the instrumentation was then removed and the animals 
were allowed to recover with buprenorphine i.m. (a synthetic opiate-receptor agonist 
analgesic) 0.03 mg/kg.day. The haemodynamic variables were recorded again at one 
week post-infarct, after anaesthesia and re-instrumentation (Figure 3.1; page 72).
3.2 PROCEDURE.
The animals were immobilised using ketamine 10 mg/kg intramuscularly. A 20-gauge 
Jelco cannula, linked to an infusion set with a distal Y-injection site, was introduced 
into a dorsal vein of the left upper-limb forearm. A slow infusion of 0.9% Na+Cl‘ in
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water (Normal Saline, Sabax) was administered using a Sabax Buretrol Paediatric 
micro-dropper set. Each experimental subject was repeatedly cleansed with Hibitane-in- 
water solution and the chest shaved of any hair, before being transported to a sterile 
operating theatre where the animal was moved to a horizontal operating table.
A rectal thermocouple was inserted and an electrical heating pad used to maintain core 
body temperature at 37° Celsius. The subject’s anaesthesia was then induced by means 
of an anaesthetic mask applied over the nasal and oral cavities (a mask was 
manufactured by the author to fit the baboons facial anatomy, thereby creating an 
acceptable seal). The induction agents used were a combination of the immobilising 
dose of ketamine and an inhalational volatile agent, halothane. Once Stage III of 
surgical anaesthesia was obtained (as judged by pupillary diameter, pupillary reflexes, 
corneal reflexes, lacrimation and muscle tone), the baboon was pre-oxygenated with 
100% inspired oxygen. The anaesthetic was delivered through a Boyle’s apparatus using 
a Magill anaesthetic circuit which incorporated a one-way expiratory valve near the 
baboon’s mask. The oxygen flow rate was regulated with a calibrated rotameter 
(Coxeter King, England) and the concentration of halothane varied by means of a pre­
calibrated Fluotec Mark II vaporiser (Cyprane Ltd. Keighley, England).
Following induction the animal was endotracheally intubated after tracheal suction, 
under laryngoscopic guidance. Depolarising and non-depolarising nicotinic-receptor 
neuro-muscular junction blockers for muscle relaxation were not used in this 
experiment. Maintenance of anaesthesia was effected with halothane at 0.5% to 1.5%
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inspired concentrations, and the baboon was ventilated on medical air and oxygen with 
an open circuit dual-phase respirator (Harvard and Bodine Electric Co., U.S.A.). The 
gas flow rates, tidal volume and ventilation rate were adjusted to support physiological 
acid-base conditions, according to frequent arterial blood gas measurements (Corning 
Analyzer; Medfield, Massachusetts). Vital life-support systems were connected to 
electrical outlets with back-up generators in the event of a power failure. In view of the 
high incidence of ventricular fibrillation following myocardial ischaemia in captivated 
baboons (Opie et al. 1983), a lignocaine infusion was administered i.v. at 10 ^g/kg.min 
as a prophylactic anti-arrythmic agent for the duration of the surgical procedures. This 
prophylactic procedure has been previously used during baboon experimental 
myocardial infarction (Geary et al. 1983).
3.3 INSTRUMENTATION.
Electrocardiography standard vertical leads I, II and III were connected to the animal 
by subcutaneous needles, to detect and monitor arrythmias and ischaemia. Observing 
theatre sterility precautions, a midline sternotomy was performed and the heart exposed 
by suspension in a pericardial cradle. In five of the animals a 5-French catheter was 
introduced into the aorta via the right common carotid artery, which was ligated (Figure 
3.2; page 74). Due to embolic phenomena (anti-coagulation was inappropriate for this 
experiment) an 18-gauge teflon-coated cannula was introduced directly into the 
ascending aortic arch in the remaining animals, with sham right common carotid arterial 
ligation. Six of the ketanserin group and four of the control group received the latter
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procedure. A 20-gauge cannula was introduced into the left atrium in all the baboons.
High-frequency conduction, saline-filled and heparin-free catheter lines were connected 
to magnetic-coiled dome pressure transducers (Statham-Gould P50; Oxnard, California), 
for the measurement of mean aortic (MAP) and mean left atrial (LAP) pressures and 
heart rate (HR). The transducers were located at mid-heart level. Aortic flow was 
measured using an electromagnetic probe (Narcomatic series-500; Houston, Texas) 
placed around the ascending aorta. The flow probe sizes were chosen, according to the 
size of the aorta, to fit tightly around the external aortic wall circumference. An 
electromagnetic flux-transparent jelly was applied to the probes to increase transmission 
of the electromagnetic field. Haemodynamic measurements were recorded in digital and 
analogue form on a multichannel recorder (Hellige Servomed; Freiburg, Germany) after 
the halothane concentration was adjusted to obtain the least possible cardiovascular 
depressive effect yet still allowing for adequate anaesthesia.
The left anterior descending coronary artery was dissected and ligated at approximately 
it’s midpoint, below the first diagonal branch. Care was taken to ensure that the 
adjacent coronary vein was not included in the ligation. The artery was then clamped 
5 millimetres proximal to the ligation and 20u bovine thrombin (Thrombostat, Parke- 
Davis) in 0.9% saline injected into the arterial sac created to produce a thrombus 
(Figure 3.3; page 76). The clamp was removed after 20 min (technique modified from 
previously described procedures: Schaub et al. 1976; Schaub et al. 1977). The ability 
of the bovine thrombin to coagulate baboon whole blood was confirmed in vitro prior
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to the experimental procedure.
During the surgical procedure, blood loss, as judged by the number of blood-saturated 
surgical swabs and the volume of blood in the suction bottle, was replaced with 
intravenous fluids. Blood loss was minimised by the use of an electro-cautery and 
electro-cutting apparatus (Birtcher 755, California, U.S.A.). Following myocardial 
infarction and the second set of haemodynamic measurements the catheters were 
removed, the pericardium re-opposed and the chest closed in layers using Vicryl suture 
material. Sternal closure was secured with synthetic Vetafil. A triple antibiotic regime 
consisting of ampicillin (broad spectrum penicillin), gentamycin (an aminoglycoside for 
gram negative bacteria cover) and Flagyl (metrinidazole; anaerobic bacteria cover) was 
used i.v. intra-operatively and i.m. post-operatively to minimise thoracic cavity 
infection.
After these initial procedures the anaesthetic was terminated and the animal was 
returned to the cage once the recommencement of spontaneous respiration had been 
ensured. Seven days after myocardial infarction the animal was again subjected to 
anaesthesia, sternotomy and instrumentation as described above. A third set of 
haemodynamic measurements was made and the baboon was euthenased by using an 
excess i.v. bolus injection of barbiturate (to effect central nervous system depression) 
and excess potassium chloride (to arrest the heart in flaccidity).
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3.4 REGIONAL MYOCARDIAL BLOOD FLOW.
Fifteen pun diameter Nen-Trac 113Sn, 85Sr and 46Sc radioactive microspheres suspended 
in 0.9 % saline with 0.01 % Tween 80 added were injected over 10 s into the left 
atrium immediately following the haemodynamic recordings, after agitation and 
sonication, according to previously described techniques (Buckberg et al. 1971: 
Heymann et al. 1977: Plus see Literature Review section 2.4.2). The microspheres 
were flushed into the atrium with saline and a simultaneous reference blood sample was 
withdrawn from the indwelling aortic cannula at 10 ml.min-1 for 2 minutes.
Post-mortem the heart was immediately excised and washed in saline. The ventricles 
were trimmed of all fat, viewed and sectioned from apex to base at 1 cm intervals 
(Figure 3.4; page 78). The full-thickness ventricle wall containing the infarct, which 
was clearly defined, was excised with a 1-2 mm edge of macroscopically non-infarcted 
myocardium to include the border zone. These infarct-ischemic segments, along with 
the remaining normal myocardial tissue segments, were weighed and dissolved in nitric 
acid for gamma-ray scintillation spectrometry (Packard 500C; Illinois, USA). Total 
infarct-ischemic myocardium and normal myocardium blood flows were calculated using 
a spectral distribution stripping technique (Heymann et al. 1977; Plus see Literature 
Review section 2.4.2). After the removal of tissues to be counted, the baboon was 
returned to the Central Animal Service for concreting and safe disposal. All the 
researchers involved were registered radiation workers, and subject to radiation 
dosimetry monitoring.
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Figure 3.1: Sequential steps of the study design. HM = haemodynamic 
measurements; RM = radioactive microsphere injection.
ANAESTHESIA (DAY 0) EUTHANASIA
I t
STERNOTOMY HM + RM
; t
INSTRUMENTATION INSTRUMENTATION
l t
HM + RM STERNOTOMY
i t
CORONARY ARTERY LIGATION ANAESTHESIA (DAY 7)
i t
HM + RM RECOVERY
i t
INSTRUMENTS REMOVED - ANAESTHESIA TERMINATED
Figure 3.2: Diagram depicting the placement of the aortic and left 
atrial cannulas and the electromagnetic flow probe.
The aortic cannula was later introduced directly through
the aortic wall into the aortic arch.
PRESSURE TRANSDUCER 
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OPEN CHEST MODEL.
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Figure 3.3: Schematic illustration of coronary artery ligation 
and thrombus induction.
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Figure 3.4: Schematic illustration of myocardial sectioning for tissue 
radioactivity analysis. The shaded areas represent the 
infarct zone, around which a 1 - 2 mm edge of normal tissue 
was included in each sample.
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3.5 CALIBRATION AND VALIDATION.
Prior to blood pressure measurements the recording system was calibrated as follows: 
An internal electronic linearity millivoltage check was first performed on the digital 
screen and the analogue recorder displays. The pressure transducers were then zeroed 
relative to atmosphere and a manual calibration performed against either a mercury 
manometer (Baumanometer) for the aortic pressure channel, or a pure-water manometer 
for the left atrial pressure transducer. The water manometer was manufactured by the 
author to increase the accuracy of pressure calibration over the range 0 - 1 5  mm Hg: 
a pressure of 1 mm Hg is equal to 13.61 mm H20 . The electromagnetic flow probe 
was zeroed against motionless fluid and thereafter an internal electronic calibration 
performed, before application of the probe to the ascending aorta.
Just prior to the injection of the microspheres a drop of the vortexed and sonicated 
sphere suspension was placed on a slide and examined with low-power light microscopy 
to ensure the absence of significant microsphere aggregation. The syringes and tubing, 
through which the microspheres had been flushed into the atrium, were also divided into 
smaller pieces after the surgery and their radio-activity checked to ensure that no 
significant amount of microspheres remained behind in these items. In addition, the left 
and right kidney radioactivity was compared to verify adequate mixing of the 
microspheres within the bloodstream.
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Coronary thrombus formation was confirmed histologically: Post-mortem the LAD 
coronary artery was removed and fixed in 10% formaldehyde. The specimens were then 
impregnated in a paraffin wax and sectioned manually with a microtome at 0.5 ^m 
intervals. The specimens were slide-mounted and stained with Hematoxylin and Eosin. 
The slides were examined microscopically for the presence of intracoronary thrombus 
formation, lamination and organisation. The presence of the macroscopically obvious 
myocardial infarction was also verified histologically.
3.6 CALCULATIONS.
The method of regional blood flow calculation is discussed in the Literature Review 
(section 2.4.2.4.). Pulse pressure (PP) is obtained from the difference of systolic 
pressure (SP) and diastolic blood pressure (DP). The mean arterial pressure (MAP) may 
be obtained from the formula;
MAP = 1/3(PP) +  DP = 1/3(SP-DP) + DP = 1/3SP +2/3DP.
This formula assumes that diastole occupies 2/3 of the cardiac cycle time, which is 
untrue for states of tachycardia. However, an electronically derived mean is independent 
of heart rate and therefore in this study the MAP is taken as the electronic mean of the 
aortic pressure cycle. Heart rate (HR) is taken as the number of systoles per unit time. 
Cardiac output is taken as the electronic mean over 10s to allow for variations of 
venous return with respiratory movements (although this variation is not marked in the
81
open-chest animal on positive pressure ventilation). Stroke volume (SV) is calculated 
from the division of CO by HR. Systemic vascular resistance is derived from the 
principle inherent in Ohm’s law;
I = V/R
Where I = The current, in amperes.
V = The potential difference, in volts.
R = The resistance of the conductor to flow, in Ohms.
This principle can be applied to any point of the biological cardiovascular system:
F = AP/R
Where F = Flow of blood.
AP = The gradient of blood pressure in the section of the closed circuit. 
R = The resistance of the blood vessels to flow.
Therefore,
CO = (MAP - RAP)/SVR
Where CO = Cardiac output in i .min'1
82
MAP = Mean arterial pressure in mm Hg.
RAP = Right atrial pressure in mm Hg (assumed to be zero in the absence of 
right ventricular failure).
SYR = The systemic vascular resistance in mm Hg.min/f
3.7 STATISTICS.
All data are given as means + SEM. The Kruskal-Wallis method and Wilcoxon 
matched pairs signed-ranks test for intragroup and the Mann-Whitney test for intergroup 
comparisons were used (Zar, 1974). A two-tailed probability of < 0.05 was taken as 
statistically significant.
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CHAPTER 4: RESULTS.
4.1 BLOOD CHEMISTRY.
The absorption of ketanserin following i.m. injection in baboons was confirmed by high 
pressure liquid chromatographic assay of serum levels (HPLC method, Janssen 
Pharmaceutica, Belgium). The serum levels were 1562 ±  395 ng/ml at 10 min after 
administration in 7 animals and 69 ± 9 ng/ml at 2 h post-administration in 3 animals.
Table 4.1 (page 84) shows pre-experimental, in-captivity electrolyte concentrations and 
haematology indices of the animals used for experimentation. The values were similar 
between the control (n = 6) and ketanserin (n = 9) groups and are in agreement with 
previously described values for Papio ursinus baboons (Steyn et al. 1975).
4.2 HISTOLOGY.
Coronary thrombus formation and myocardial infarction were successfully produced 
using the methods described. Figure 4.1 (page 86) illustrates the typical laminated 
thrombi which results from coronary artery ligation and the injection of thrombin. The 
thrombi showed organisation and, in some cases, early recanalisation. Figure 4.2 (page 
88) illustrates sections of the left ventricular organising infarcts one week after coronary 
artery ligation.
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TABLE 4.1
BLOOD CHEMISTRY VALUES OF PAPIO URSINUS BABOONS IN CAPTIVITY.
BLOOD TEST (value ± SD) CONTROL KETANSERIN COMBINED
Sodium (mmol/f) 144.7 ±  1.4 144.3 ±  2.4 144.5 ±  2.0
Potassium (mmol/£) 3.9 ±  0.3 4.0 ±  0.8 3.9 ±  0.7
Haemoglobin (g/dT) 13.9 ±  1.2 14.9 ±  1.3 14.5 ±  1.3
Red cell count (x 1012/T) 5.7 ±  0.5 5.9 ±  0.6 5.8 ±  0.6
Haematocrit (ratio) 0.431 ±  0.032 0.460 ±  0.035 0.446 ±  0.036
Mean cell volume (f£) 75.8 ±  3.5 78.2 ± 3.7 77.1 ±  3.7
Mean cell haemoglobin (pg) 24.5 ±  1.2 25.4 ±  1.0 25.0 ±  1.1
Mean cell haemoglobin concentration (g/d£) 32.3 ±  1.3 32.5 ±  1.2 32.4 ±  1.2
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FIGURE 4.1;
Sections of the baboons’ coronary arteries proximal to the site of ligation, viewed 
and photographed under the light microscope.
The top plate shows a cross section of the LAD artery, stained with Hematoxylin and 
Eosin, one week following it’s ligation. A large thrombus is situated within the lumen 
and is adherent to the intimal surface of the blood vessel wall at the inferior aspect of 
the lumen (bottom end of the photograph). The thrombus contains fibrin layers (pale 
areas at top right of the lumen) enmeshing platelets. Trapped in the fibrin-platelet mass 
are scattered red blood cells as well as white blood cells, most of which are eosinophils. 
There is invasion by fibroblasts and capillaries on the inferior intimal surface, indicative 
of early organisation and recanalisation of the thrombus. The lumen is surrounded by 
a well defined arterial muscular media.
The middle and bottom plates demonstrate a different LAD artery at low and high 
power fields, one week following ligation of the artery. The arterial lumen is entirely 
obliterated by thrombus. Specific Giemsa staining techniques highlight the platelet and 
fibrin layers indicative of an ante-mortem thrombus.
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FIGURE 4.2
Sections of the baboons’ myocardium demonstrating ventricular myocardial 
infarction.
The top plate shows a hematoxylin and eosin stained section of the myocardium under 
low power light microscopy. The deeply eosinophilic areas are the infarcted cardiac 
muscle. The edges of the infarct are invaded with inflammatory cells forming 
granulation tissue.
The middle plate shows a hematoxylin and eosin section of the left ventricular 
myocardium at one week. The infarcted dead muscle (lower right) stains deeply and 
and lacks nuclei. The ischaemic and living muscle fibres stain more palely and are 
nucleated.
The lower plate shows a high power section of the infarcted myocardium. The muscle 
fibres are still striated, but deeply eosinophilic and without nuclei. Between the cardiac 
muscle fibres are polymorphs, macrophages and fibroblasts, which later digest the dead
muscle and form scar tissue.
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4.3 HAEMODYNAMICS.
There was no difference in the incidence of ventricular fibrillation between the two 
groups; three ketanserin and two control animals were low-amperage direct-current 
cardioverted for ventricular fibrillation following coronary artery ligation.
Table 4.2 (page 90) and Table 4.3 (page 91) present the haemodynamics recorded 
before, after (mean 4 5 + 9  min after coronary occlusion) and 7 days after coronary 
artery ligation in the ketanserin and control groups. MAP and aortic flow were similar 
within and between both groups, and did not therefore influence the regional myocardial 
blood flow measurement interpretations. Systemic vascular resistance in the ketanserin 
group was not significantly different from the control group. The LAP increments noted 
post-occlusion were not significant in both groups. The HR increase at 7 days was 
significant within the ketanserin group only.
An example of the coronary angiography, performed in the early part of the 
experiments only, is shown in Figure 4.3 (page 93). The angiographic method of 
collateral assay was discontinued due to high morbidity rates associated with the 
prolonged anaesthesia required to include this technique, and because of the poor 
visualisation of collaterals using this procedure (see Literature Review, section 2.4.1.)
TABLE 4.2: HAEMODYNAMICS AFTER KETANSERIN ADMINISTRATION AND CORONARY OCCLUSION.
SP DP MAP PP LAP
Treatment Time (mm Hg) (mm Hg) (mm Hg) (mm Hg) (mm Hg)
Ketanserin Pre-occlusion 92 ±  5.0 71 ±  3.5 82 ±  3.8 26 ±  2.5 5.6 ±  0.9
45 min post-occlusion 88 ±  5.4 69 ±  3.8 79 ±  4.2 23 ±  1.8 7.1 ±  1.0
7 days post-occlusion 71 ±  4.8 62 ±  4.2 75 + 4.5 26 + 3.0 9.3 ±  1.1
Placebo Pre-occlusion 97 ±  1.9 73 ±  1.7 85 ±  1.7 24 ±  0.9 5.2 ±  0.9
45 min post-occlusion 87 ±  7.1 65 ±  5.9 77 ±  6.1 22 ±  1.8 6.0 +  1.3
7 days post-occlusion 90 ± 5.0 63 ±  2.7 75 ±  3.8 27 + 3.4 6.7 +  1.0
SP = Systolic pressure; DP = Diastolic pressure; MAP = mean aortic pressure; PP = pulse pressure; 
LAP = mean left atrial pressure.
TABLE 4.3: HAEMODYNAMICS AFTER KETANSERIN ADMINISTRATION AND CORONARY OCCLUSION.
HR CO SV SVR
Treatment Time (beats/min) (f/min) (ml) (mm Hg.min/1)
Ketanserin Pre-occlusion 102 ±  5.1 1.12 ±  0.11 11.3 ±  1.27 78.4 ±  5.8
45 min post-occlusion 105 ±  2.6 0.99 ±  0.09 9.52 +0.97 84.0 ±  6.6
7 days post-occlusion 118 ±  4.1* 1.19 ±  0.11 10.3 ±  1.25 66.8 ±  8.1
Placebo Pre-occlusion 101 ±  6.8 1.02 + 0.05 10.3 ±  0.97 84.5 ±  4.3
45 min post-occlusion 106 ±  7.1 1.11 ±  0.12 10.7 + 1.41 70.4 ±  3.9
7 days post-occlusion 116 ±  4.9 0.95 + 0.06 8.3 ±  0.72 79.3 + 3.9
HR = heart rate; CO = mean aortic blood flow; SV = mean left ventricular stroke volume; 
SVR = systemic vascular resistance. ap < 0.05, significantly different from 
ketanserin pre-occlusion and 45 min post-occlusion.
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FIGURE 4.3 :
Coronary angiography of the baboon heart prior to coronary artery ligation.
The photographs show antero-posterior and lateral views of the heart after the injection 
of radio-opaque Urograffin* dye. The definition obtained is not sufficient for the 
quantification of smaller collaterals, which may be microscopic in size (See Literature 
Review section 2.4.1 paragraph 2).
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FIGURE 4.3 :
Coronary angiography of the baboon heart prior to coronary artery ligation.
The photographs show antero-posterior and lateral views of the heart after the injection 
of radio-opaque Urograffm* dye. The definition obtained is not sufficient for the 
quantification of smaller collaterals, which may be microscopic in size (See Literature 
Review section 2.4.1 paragraph 2).
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Infarct size, calculated from the infarcted ventricular tissue: total ventricular weight 
ratio, was 15.3 + 2.8% and 16.1 ±  0.8% in the ketanserin and control groups 
respectively (Figure 4.4, page 96). The mean heart ventricle:body weight ratio at one 
week was 0.3 + 0.01% in both groups. The mean weight of both groups’ myocardial 
tissue samples (which were counted for radioactivity) was 1.29 ±  0.02 grams/sample 
(interquartile range 0.8 - 1.7 grams).
Table 4.4 (page 97) presents the ventricular blood flows to the normal and the infarct- 
ischemic areas before, 45 min after and 7 days after coronary artery occlusion. Pre­
occlusion regional blood flows were the same in both groups. The ratio of the blood 
flow in the infarct-ischemic left ventricular myocardium to that of the normal 
ventricular myocardium shows an expected decrease post-coronary artery occlusion on 
day 0, when compared with the pre-occlusion value (Figure 4.5, page 99). This 
decrease is significant (p < 0.05) and similar in both groups. At 7 days post-occlusion 
both groups show a significant (p < 0.05) but equal increase in this ratio compared 
with day 0 post-occlusion, suggesting a similar improvement of regional blood flow to 
the infarct-ischemic area at 7 days in both groups.
4.4 REGIONAL BLOOD FLOWS.
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Figure 4.4
Infarct size resultant upon mid-length left anterior descending coronary artery ligation 
in the Papio ursinus baboon. Similar sized infarctions were produced in both the control 
and ketanserin groups.
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TABLE 4.4. Effect of ketanserin and coronary occlusion on regional myocardial blood flow
Treatment
Time
Regional blood flow ml/min.lOOg 
Infarct-ischemic ventricle Normal ventricle
Ketanserin A. Pre-occlusion 51.9 ±  3.8 62.1 ±  7.3
B. 45 min post-occlusion 28.4 ±  2.8a 72.1 ±  9.1c
C. 7 days post-occlusion 63.8 ±  6.1 102.9 ±  10.8bc
Placebo D. Pre-occlusion 50.0 ± 6.6 60.7 + 9.9
E. 45 min post-occlusion 19.8 ± 3.6“ 59.2 + l . T
F. 7 days post-occlusion 53.7 ±  6.9 97.0 + 12.4M
*p < 0.05 for infarct-ischemic ventricle; B vs. A and C, E vs. D and F. 
bp < 0.05 for normal ventricle; C vs. A and B, F vs. D and E. 
cp < 0.01 for; normal ventricle B vs. infarct-ischemic B; normal 
ventricle C vs. infarct-ischemic C.
‘‘p < 0.01 for; normal ventricle E vs. infarct-ischemic E; normal 
ventricle F vs. infarct-ischemic F.
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FIGURE 4.5
The effect of ketanserin on the ratio of infarct-ischaemic ventricle:normal ventricle 
blood flow, before and after coronary occlusion. Occ. = occlusion. For both groups; 
+p < 0.05 significantly lower than day 0 pre-occlusion; *p < 0.05 significantly greater 
than day 0 post-occlusion and significantly less than day 0 pre-occlusion.
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CHAPTER 5: DISCUSSION.
5.1 HAEMODYNAMICS.
The LAP increments post-occlusion were not significant in both groups. This latter 
finding agrees with a previously noted absence of significant chronic increments in left 
ventricular end diastolic pressure following anterior descending coronary artery 
occlusion, in baboons (Crozatier et al. 1978). The HR increase at 7 days, which was 
significant within the ketanserin group only, may be a cumulative response to 
ketanserin’s effect of increasing circulating catecholamines (Grobecker et al. 1985).
Hypokalemia has been advocated as a predisposing factor for cardiac arrhythmias in 
captivated baboons (Opie et al. 1983). The baboon serum potassium levels measured 
in captivity, prior to experimentation, in my study were within the normal range for 
most primates (Steyn et al. 1975). Hypokalemia was therefore unlikely to have been 
an associated causative factor for ventricular fibrillation in this experiment. The use of 
halothane anaesthesia is however well recognised to increase the sensitivity of the 
myocardium to circulating catecholamines, thereby exacerbating the arrythmic potential
of the heart under ischaemic conditions.
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5.2 KETANSERIN AND REGIONAL BLOOD FLOW.
The results show that 5-HT2 receptor antagonism in baboons has no effect on regional 
myocardial blood flow in the infarct-ischaemic areas or in the normal myocardial areas 
immediately and one week after thrombotic left anterior descending coronary artery 
occlusion. Perfusion of the ischaemic-infarct myocardial areas does however increase 
relative to the non-infarcted regions at one week, in both groups (Figure 4.5; page 99). 
This increment of regional blood flow can be attributed either to functional collateral 
formation over this period, or to selective coronary vasodilation of the inflamed 
ischaemic myocardial areas at one week. Collateral formation is, however, the more 
likely mechanism involved here, since inflammatory-related vasodilation in the 
ischaemic areas would already have formed at the time of the second radioactive 
microsphere measurements (i.e. 45 min after coronary ligation). In addition, early 
collateral blood supply to the myocardium at risk, in the absence of inflammation, has 
previously been implicated in baboons following coronary occlusion (Lubbe et al. 
1974). Furthermore, the myocardial collateral circulation following coronary artery 
ligation in baboons has also previously been shown to increase over one month 
(Crozatier et al. 1978).
Thus ketanserin does not appear to affect the functional extent of the collateral 
circulation which exists at the time of occlusion, nor it’s functional development over 
one week. In addition, prior to coronary artery occlusion in both groups, the pre-infarct 
left ventricular apex had a similar blood flow to the remainder of the ventricles,
102
suggesting that ketanserin does not alter the typical distribution of myocardial blood 
flow in the normal baboon heart.
5.3 KETANSERIN AND INFARCT SIZE.
In keeping with this study’s findings that no difference in the infarct-ischaemic zone 
blood flows or most haemodynamic variables was found between the two groups and, 
with the premise that the site of coronary occlusion and the myocardial region at risk 
were similar in both groups, infarct size was also not affected by ketanserin. This result 
agrees with a recent observation that LY53857, a selective 5-HT2 antagonist, did not 
alter infarct size in dogs following 90 min of coronary artery occlusion (Simpson et al. 
1991).
In my study the female baboon total ventricle weight:body weight ratio (3.3 +  0.3 
g/kg, n = 15) is lower than the male baboon heart weight:body weight ratios found by 
Weisse et al. 1976 (5.2 ±  0.3 g/kg, n = 16) and Maxwell et al. 1987 (8.6 g/kg, n = 
6). Atrial weight was not included in the ratio used for my study, which partially 
explains the difference. Apart from the study animal sex differences, Weisse et al. ’s 
study fails to mention the species of baboon used, while the baboon species used in the 
Maxwell et al. study was Papio anubis and not the Papio ursinus used in my study.
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5.4 MICROSPHERE LOSS.
The measured increase in the regional myocardial blood flows of both the infarct- 
ischaemic and the normal myocardium at one week, in both groups, is contributed to 
by a number of factors: Firstly, the time-related loss of microspheres from myocardium 
has been described in various experimental animals (Marshall et al. 1976; Judgutt et 
al. 1979; Lekuen and Andersein, 1980; Consigny et al. 1982). This loss would 
contribute to the higher radioactive microsphere tissue counts of the isotope used at day 
7 compared with the two isotopes used at day 0, since the animals were euthenased 
immediately following the day 7 isotope injection. The loss of 15/xm microspheres from 
ischaemic myocardium was 26% over 10 hours in one canine study (Lekuen and 
Andersein, 1980), whilst the quantity of chronic microsphere loss from the normal and 
ischaemic canine myocardium was found to be similar from both these areas (Consigny 
et al. 1982): In addition, the use of halothane anaesthesia increased the total myocardial 
microsphere loss in this latter study.
The microsphere loss phenomenon has not been extensively investigated in baboons. 
Our data, in agreement with a previous baboon study (Lavallee and Vatner, 1984), 
show no significant difference between the pre-occlusion infarct-ischaemic zone and the 
normal zone myocardial blood flows. This fact does not however exclude chronic 
myocardial microsphere loss, but verifies that, in baboons, any chronic microsphere 
loss which occurs from the infarct-ischaemic zone is similar to that of the normal zone.
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The presence of tissue oedema or haemorrhage in the infarct-ischaemic zone has been 
implicated as an interfering factor in the interpretation of microsphere-derived regional 
blood flows following myocardial infarction (Reimer and Jennings, 1979). Since, in this 
study, the pre-occlusion ischaemic-infarct zone blood flows were not significantly 
different to the normal zone pre-occlusion blood flows (which finding would not be 
expected if post-occlusion oedema or haemorrhage had subsequently increased the 
weight of the ischaemic-infarct zone, thereby artificially reducing the calculated blood 
flows), this influence could not have interfered with my interpretation of the myocardial 
collateral blood flow data or infarct size.
A second factor which may have contributed to the increased myocardial blood flows, 
in both the normal and the infarct-ischaemic myocardium at one week, is the trend 
towards an increased heart rate in both groups at this time. This increment in heart rate 
may have produced autoregulatory coronary vasodilation with the greater oxygen 
demand imposed on the myocardium. Since I have used the ratio of infarct- 
ischaemicinormal myocardium blood flow to demonstrate that ketanserin has no effect 
on collateral formation, the above-mentioned factors would not have interfered with this 
interpretation of my data.
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5.5 SEROTONIN ANTAGONISM.
The dose of ketanserin administered in this study is known to produce 5-HT2 receptor 
blockade in several animal models, and is comparable with the 1.25 mg/kg.day used 
by Nevelsteen et al. 1984. The 2 h plasma concentration of ketanserin measured in the 
baboons is similar to the concentration required to block serotonin induced dog 
coronary artery constriction (Brazenor and Angus, 1982) and to the concentration found 
following a 10 mg i.m. or i.v. bolus injection in humans (Heykants et al. 1986). The 
study data were not significantly affected by post-junctional cq-adrenoreceptor blockade 
since there was no change in the blood pressure measurements at any time with the 
dose of 1 mg/kg ketanserin daily.
Intra-arterial infused serotonin is vasoactive in coronary arteries, mediating 
vasoconstriction, vasodilation and cyclic flow variations in different species (Lamping 
et al. 1985; Ashton et al. 1986; Bush, 1987; Chu and Cobb, 1987). In my study, in 
order to approach the pathophysiological conditions of myocardial disease more closely, 
no exogenous serotonin was infused, the use of heparin was avoided and thrombin was 
injected locally to mediate platelet aggregation. These procedures are unlike most other 
serotonin investigations which have been performed to date, since serotonin was usually 
injected as an exogenous agent in these studies.
Although 5-HT2 receptor antagonism has often been shown to reverse serotonin-induced 
coronary artery constriction, the exact role of serotonin in ischaemic heart disease is
106
still controversial, and my findings corroborate those of many other researchers: It has 
been noted that in swine epicardial and transmural regional blood flows were not 
affected by serotonin infusion following coronary artery stenosis (Ruocco et al. 1988). 
Platelet-activating factor has been shown to restore cyclic blood flow variations (CFV’s) 
in stenosed canine coronary arteries despite pre-treatment with ketanserin (Apprill et 
al. 1985); ketanserin did not significantly attenuate the delayed vasoconstrictor response 
to infused serotonin in awake dog proximal coronary arteries (Chu and Cobb, 1987) 
and ketanserin, given by itself, did not prevent the re-occlusion of thrombolysed canine 
coronary artery thrombosis, where the combination of both ketanserin and a 
thromboxane A2/prostaglandin H2-receptor antagonist did produce a deterrent effect 
(Golino et al. 1988). In addition, the non-selective serotonin antagonist methysergide, 
but not ketanserin, was found to abolish serotonin-induced reductions in blood flow 
following canine dynamic coronary artery stenosis (Ichikawa et al. 1989). Our primate 
data also support the findings that ergonovine-induced myocardial ischemia (Freedman 
et al. 1984) and Prinzmetal’s angina (De Caterina et al. 1984) are not improved by the
administration of ketanserin in humans.
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5.6 CONCLUSION.
I have shown that 5-HT2 receptor antagonism does not potentiate coronary vasodilation, 
regulate ischaemic zone blood flow or modify functional collateral formation in 
anaesthetized baboons following acute thrombotic coronary artery occlusion, and that 
ketanserin has neither a protective nor an adverse effect on the resulting myocardial 
infarct. Since the possible routine use of serotonin antagonists for the management of 
human ischaemic heart disease is a current issue, my findings necessitate further 
investigation into the exact roles of serotonin, the identification of serotonergic 
receptors and the potential use of combinations of 5-HT2 receptor antagonists with 
thromboxane-A2 inhibitors or with 5-HTr like receptor antagonists, in these non-human 
primates.
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APPLICATION FOR CLEARANCE OF USE OF RADIOACTIVE ISOTOPES/ 
IONISING RADIATIONS IN AN ANIMAL EXPERIMENT
(Including neutral nuclear beam* but excluding X-ray radiographic procedure*).
1. Which ionising radiations are to be used?
Radioactive Material* Machine Produced
Type Activity ^Ci or Sq) Type Dose (Gy)
1 5 u m  R a d i o - l a b e l l e d ,  m i c r o s h p e r e s ................... x - r  a  v . 2 . 0 .  m i n s . . x . . 4 . .  s e s s i o n s
n  n  ,• r* 4 ( t o t a l  o f  8 0  m i n s  p e r  a n i m a
S t r o n t i u m son
1 4 1  •
C e r i u m son u C i
1 1  9 . n . 
p i n son u C i
2. For radioactive nuclides indicate:
(i) Where dispensing and administration will be done
Room No...... ..................................................
Building ..... We.dica 1. .S .ch o o L ,. .York . B a a r t .R a r k .ta v n
(ii) The quantities of radioactive materials to be given to each animal
. . . .  2 3 .  . u . C i . o f .  . e . a c h . .  i . s o t o p j e ..........................................................................
(iii) Where the animals Will be housed, sampled and killed
. . flp.use.4. . i n . fie .o t.ra l .Anlina 1 .U n it.... . . F.apip.lft. fiCU3 ..... K i l l e d . .6M13 .
...Cp.ocrst.ed.by..Centra.!. Animal..Unit.......................
t>v) Where tne examination and measurement of carcase material, organs body fluids etc. will be 
carried out
. .  $ M i 3 ; . . C e n f c r  a l . . S . c i n . t i . l l a . t i . o a .  C o u n t  e . r .  . S e r v i c e .......................................................
(v) With wfiich instruments tne measurements will be made
. A u t o . g a m m a  S c i n t i l l a t i o n  S p e c t r o m e t e r
Applicant's Signature Oete V.P.Y.SfUel No. ibn..?iv?2> /izri,
FOR ADMINISTRATIVE USE ONLY
APPROVED 0 ^ NOT APPROVED [ H
Instruction lor mode of disposal of carcase material/organs/body fluids:
1. Incineration without 
any restrictions. □ 2. Storage under □ 3. Incapsulate in | . Vrefrigeration for lime for disposal 1
___days before to A C E  by Health
incineration. Physics Service.
Comments and Recommendations:
Director of Health Physics Service 
or Deputising Officer
Date
NOTE
Queries regarding the completion of this form should be directed to Professor R J Keddy at the’ 
Schonland Research Centre Tel. Eat. 3163.
CM
